CN102791688B - Estrogen receptor ligands - Google Patents
Estrogen receptor ligands Download PDFInfo
- Publication number
- CN102791688B CN102791688B CN201080045502.6A CN201080045502A CN102791688B CN 102791688 B CN102791688 B CN 102791688B CN 201080045502 A CN201080045502 A CN 201080045502A CN 102791688 B CN102791688 B CN 102791688B
- Authority
- CN
- China
- Prior art keywords
- compound
- indoles
- hydroxyphenyl
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010038795 estrogen receptors Proteins 0.000 title claims abstract description 72
- 102000015694 estrogen receptors Human genes 0.000 title claims abstract 10
- 239000003446 ligand Substances 0.000 title claims description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 144
- 150000001408 amides Chemical class 0.000 claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000035475 disorder Diseases 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims description 64
- -1 heterocyclic radical Chemical class 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 48
- 238000002360 preparation method Methods 0.000 claims description 38
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000000623 heterocyclic group Chemical group 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 21
- 150000002367 halogens Chemical class 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 150000003254 radicals Chemical group 0.000 claims description 17
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000001132 Osteoporosis Diseases 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 201000009273 Endometriosis Diseases 0.000 claims description 9
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 9
- 208000024827 Alzheimer disease Diseases 0.000 claims description 8
- 208000024732 dysthymic disease Diseases 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 206010060800 Hot flush Diseases 0.000 claims description 7
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 7
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 201000009916 Postpartum depression Diseases 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 206010065687 Bone loss Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000020401 Depressive disease Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 206010021639 Incontinence Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 201000007737 Retinal degeneration Diseases 0.000 claims description 5
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 5
- 210000000845 cartilage Anatomy 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 239000011737 fluorine Substances 0.000 claims description 5
- 201000000079 gynecomastia Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 201000010260 leiomyoma Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 230000004258 retinal degeneration Effects 0.000 claims description 5
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 208000012991 uterine carcinoma Diseases 0.000 claims description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims description 5
- 206010003694 Atrophy Diseases 0.000 claims description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 206010022998 Irritability Diseases 0.000 claims description 4
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 230000037444 atrophy Effects 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000003920 cognitive function Effects 0.000 claims description 4
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 4
- 231100000867 compulsive behavior Toxicity 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- 206010004593 Bile duct cancer Diseases 0.000 claims description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 3
- 206010020651 Hyperkinesia Diseases 0.000 claims description 3
- 208000000269 Hyperkinesis Diseases 0.000 claims description 3
- 206010026749 Mania Diseases 0.000 claims description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 3
- 208000020339 Spinal injury Diseases 0.000 claims description 3
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 208000013403 hyperactivity Diseases 0.000 claims description 3
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 3
- 210000001635 urinary tract Anatomy 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 206010011796 Cystitis interstitial Diseases 0.000 claims 2
- 230000002596 correlated effect Effects 0.000 claims 2
- 201000008017 ovarian lymphoma Diseases 0.000 claims 2
- 201000003733 ovarian melanoma Diseases 0.000 claims 2
- BYNMBNAUXMYVLK-UHFFFAOYSA-N 4-[2-(3,5-dimethyl-1,2-oxazol-4-yl)-1-methylsulfonylindol-3-yl]phenol Chemical compound CC1=NOC(C)=C1C(N(C1=CC=CC=C11)S(C)(=O)=O)=C1C1=CC=C(O)C=C1 BYNMBNAUXMYVLK-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 abstract description 15
- 239000012453 solvate Substances 0.000 abstract description 11
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 102100038595 Estrogen receptor Human genes 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 57
- 125000005843 halogen group Chemical group 0.000 description 26
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- 239000002253 acid Substances 0.000 description 20
- 150000002923 oximes Chemical class 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 19
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000012043 crude product Substances 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- 239000005557 antagonist Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 239000000262 estrogen Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 229940011871 estrogen Drugs 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 102100029951 Estrogen receptor beta Human genes 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 235000012239 silicon dioxide Nutrition 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 125000000217 alkyl group Chemical group 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 101001010910 Homo sapiens Estrogen receptor beta Proteins 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000004031 partial agonist Substances 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229910001873 dinitrogen Inorganic materials 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000001294 propane Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000000935 antidepressant agent Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000012266 salt solution Substances 0.000 description 8
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000004076 pyridyl group Chemical group 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229940062527 alendronate Drugs 0.000 description 6
- 230000001076 estrogenic effect Effects 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- 230000001519 thymoleptic effect Effects 0.000 description 6
- 102100021253 Antileukoproteinase Human genes 0.000 description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 238000012797 qualification Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 229940122815 Aromatase inhibitor Drugs 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000004278 EU approved seasoning Substances 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000000949 anxiolytic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003886 aromatase inhibitor Substances 0.000 description 4
- 229940049706 benzodiazepine Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 4
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical class OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 description 4
- 229960001393 dosulepin Drugs 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 4
- 229940126569 noradrenaline reuptake inhibitor Drugs 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 125000005936 piperidyl group Chemical group 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000002821 scintillation proximity assay Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 108010041356 Estrogen Receptor beta Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 208000019022 Mood disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000003973 alkyl amines Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000328 estrogen antagonist Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 3
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 3
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 125000002769 thiazolinyl group Chemical group 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 230000001457 vasomotor Effects 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- PMVRRQSALOUNSN-UHFFFAOYSA-N (3,5-dimethyl-1,2-thiazol-4-yl)boronic acid Chemical compound CC1=NSC(C)=C1B(O)O PMVRRQSALOUNSN-UHFFFAOYSA-N 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- SXLHAMYMTUEALX-UHFFFAOYSA-N (4-methoxyphenoxy)boronic acid Chemical compound COC1=CC=C(OB(O)O)C=C1 SXLHAMYMTUEALX-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 102000004171 Cathepsin K Human genes 0.000 description 2
- 108090000625 Cathepsin K Proteins 0.000 description 2
- 229940122010 Corticotropin releasing factor antagonist Drugs 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010007005 Estrogen Receptor alpha Proteins 0.000 description 2
- 101710196141 Estrogen receptor Proteins 0.000 description 2
- 229940122880 Estrogen receptor agonist Drugs 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 description 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 229960000836 amitriptyline Drugs 0.000 description 2
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000028683 bipolar I disease Diseases 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960002495 buspirone Drugs 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000002769 corticotropin releasing factor antagonist Substances 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- ZZFKAZHZSSJSSE-UHFFFAOYSA-L disodium;[(cycloheptylamino)-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate;hydrate Chemical compound O.[Na+].[Na+].OP(O)(=O)C(P([O-])([O-])=O)NC1CCCCCC1 ZZFKAZHZSSJSSE-UHFFFAOYSA-L 0.000 description 2
- TYJOJLOWRIQYQM-UHFFFAOYSA-L disodium;phenyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OC1=CC=CC=C1 TYJOJLOWRIQYQM-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 229960002866 duloxetine Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 229940009626 etidronate Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229940015872 ibandronate Drugs 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 2
- 229950006971 incadronic acid Drugs 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000012499 inoculation medium Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 229960004815 meprobamate Drugs 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- VMMKGHQPQIEGSQ-UHFFFAOYSA-N minodronic acid Chemical compound C1=CC=CN2C(CC(O)(P(O)(O)=O)P(O)(O)=O)=CN=C21 VMMKGHQPQIEGSQ-UHFFFAOYSA-N 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229960005017 olanzapine Drugs 0.000 description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 229920002102 polyvinyl toluene Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 201000001514 prostate carcinoma Diseases 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940089617 risedronate Drugs 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- 208000012672 seasonal affective disease Diseases 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000003153 stable transfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 229940127228 tetracyclic antidepressant Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000004385 trihaloalkyl group Chemical group 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960000607 ziprasidone Drugs 0.000 description 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 1
- DIIFZCPZIRQDIJ-UHFFFAOYSA-N (3,5-dimethyl-1,2-oxazol-4-yl)boronic acid Chemical compound CC1=NOC(C)=C1B(O)O DIIFZCPZIRQDIJ-UHFFFAOYSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LRANPJDWHYRCER-UHFFFAOYSA-N 1,2-diazepine Chemical compound N1C=CC=CC=N1 LRANPJDWHYRCER-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NUVPJXUYFGWDGB-UHFFFAOYSA-N 2-[4-[[2-fluoro-3-[[4-[6-(N'-propan-2-ylcarbamimidoyl)-1H-benzimidazol-2-yl]phenoxy]methyl]phenyl]methoxy]phenyl]-N'-propan-2-yl-3H-benzimidazole-5-carboximidamide Chemical compound CC(C)NC(=N)C1=CC2=C(C=C1)N=C(N2)C1=CC=C(OCC2=CC=CC(COC3=CC=C(C=C3)C3=NC4=C(N3)C=C(C=C4)C(=N)NC(C)C)=C2F)C=C1 NUVPJXUYFGWDGB-UHFFFAOYSA-N 0.000 description 1
- JJJOZVFVARQUJV-UHFFFAOYSA-N 2-ethylhexylphosphonic acid Chemical compound CCCCC(CC)CP(O)(O)=O JJJOZVFVARQUJV-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UYEXLMLQBNGMAW-UHFFFAOYSA-N 3-(benzenesulfonyl)-1h-indole Chemical class C=1NC2=CC=CC=C2C=1S(=O)(=O)C1=CC=CC=C1 UYEXLMLQBNGMAW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QXIQBDCQUFEYPC-UHFFFAOYSA-N 4-[dimethyl(phenyl)silyl]phenol Chemical compound C=1C=C(O)C=CC=1[Si](C)(C)C1=CC=CC=C1 QXIQBDCQUFEYPC-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 229940121913 Alpha adrenoreceptor antagonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 0 CC([n]1c2c(*)c(*)c(*)c(*c3c-4c(*)c(*)c(*)c3*)c2c-4c1*)O Chemical compound CC([n]1c2c(*)c(*)c(*)c(*c3c-4c(*)c(*)c(*)c3*)c2c-4c1*)O 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229940122156 Cathepsin K inhibitor Drugs 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- BKLKNEPLLZOSHJ-UHFFFAOYSA-N Cc1c[s]c(C)c1-c([n](/C(/N)=N/O)c(c1c2)ccc2Cl)c1-c(cc1)ccc1O Chemical compound Cc1c[s]c(C)c1-c([n](/C(/N)=N/O)c(c1c2)ccc2Cl)c1-c(cc1)ccc1O BKLKNEPLLZOSHJ-UHFFFAOYSA-N 0.000 description 1
- YCMZIAXKLSELCJ-UHFFFAOYSA-N Cc1c[s]c(C)c1-c([n](c(c1c2)ccc2Cl)C#N)c1-c(cc1)ccc1O Chemical compound Cc1c[s]c(C)c1-c([n](c(c1c2)ccc2Cl)C#N)c1-c(cc1)ccc1O YCMZIAXKLSELCJ-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 229940127406 Estrogen Receptor Agonists Drugs 0.000 description 1
- 229940102550 Estrogen receptor antagonist Drugs 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 208000016621 Hearing disease Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 208000017257 LMNA-related cardiocutaneous progeria syndrome Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- FJRQZJKAZIDFQE-UHFFFAOYSA-N O(C#N)C1=CC=C(C=C1)C(C)(C)C1=CC=C(C=C1)OC#N.CCC Chemical compound O(C#N)C1=CC=C(C=C1)C(C)(C)C1=CC=C(C=C1)OC#N.CCC FJRQZJKAZIDFQE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
- 229940087098 Oxidase inhibitor Drugs 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- DCSBSVSZJRSITC-UHFFFAOYSA-M alendronate sodium trihydrate Chemical compound O.O.O.[Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O DCSBSVSZJRSITC-UHFFFAOYSA-M 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 229940015273 buspar Drugs 0.000 description 1
- IAQRGUVFOMOMEM-UHFFFAOYSA-N butene Natural products CC=CC IAQRGUVFOMOMEM-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940082484 carbomer-934 Drugs 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical class C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000007948 fast release tablet Substances 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940089256 fungistat Drugs 0.000 description 1
- UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229950011129 minodronic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 208000020629 overactive bladder Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000036178 pleiotropy Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940080350 sodium stearate Drugs 0.000 description 1
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- IAQRGUVFOMOMEM-ONEGZZNKSA-N trans-but-2-ene Chemical compound C\C=C\C IAQRGUVFOMOMEM-ONEGZZNKSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940009065 wellbutrin Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity. In the formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification.
Description
Technical field
The present invention relates to as estrogen receptor ligands (estrogen receptor ligand) and preferably to β hypotype estrogen receptor compound selectively, also relate to and prepare the method for this compounds and by the method for this compounds for treating disease relevant to estrogen receptor, described disease is dysthymia disorders (depressive disorder) for example, anxiety disorder (anxiety disorder), alzheimer's disease (Alzheimer ' s disease), cognitive disorder (cognitive disorder), osteoporosis (osteoporosis), blood triglyceride level increases (elevated blood triglyceride level), atherosclerosis (atherosclerosis), endometriosis (endometriosis), the urinary incontinence (urinary incontinence), autoimmune disorder (autoimmune disease) and lung cancer, colorectal carcinoma, mammary cancer, uterus carcinoma and prostate cancer.
Background technology
Estrogen receptor (ER) is in the participation that activates of a kind of part, to be in harmonious proportion the Mammals transcription factor of down-regulation of gene expression.The natural hormone of estrogen receptor is β-17-estradiol (E2) and closely-related metabolite.The combination of estradiol and estrogen receptor can cause receptor dimerization, subsequently this dimer again with DNA on estrogen response element (ERE ' s) combination.ER/DNA mixture can be raised other transcription factor, and described transcription factor can be responsible for ERE downstream DNA to be transcribed into mRNA, and mRNA is finally translated into protein.The intermediacy (intermediacy) of---particularly fos and jun---or ER and DNA can also pass through other transcription factor and indirectly interacting.Owing to being permitted polygenic expression and be subject to the adjusting of estrogen receptor, and estrogen receptor has expression in many cell types, so may there is material impact to the physiology of organism or physiopathology by the adjusting of estrogen receptor being carried out with the combination of natural hormone or synthetic ER part.
Past people think to only have a kind of estrogen receptor always.But someone has had been found that the second hypotype (ER-β).Although the ER-α of " classics " and the ER-β of recent findings are distributed widely in different tissues, they still demonstrate significantly different cell type and tissue distribution.So both can having retained estrogenic useful effect, the ER-α of synthetic or ER-beta selective part also can reduce undesired side effect risk.
Oestrogenic hormon is most important in female sexual development.In addition, oestrogenic hormon is keeping there is important effect aspect bone density, adjusting blood lipid level, and seems to also have neuroprotective.For example, so it is relevant with numerous disease that the estrogen production of postmenopausal women reduces, osteoporosis, atherosclerosis, depression and cognitive disorder.On the contrary, the proliferative disease of some type (as mammary cancer, uterus carcinoma and endometriosis) is to be subject to estrogen-induced, so estrogen antagonist (antiestrogens) (being estrogen antagonist) can be used for preventing and treating the disease of these types.
And, the effect that is used for the treatment of various forms of depressive illness is proved natural estrogen---17 beta estradiol---, and someone proposed estrogenic antidepressant activity may be by regulate the active and serotonin (serotonin) subsequently of tryptophan hydroxylase synthetic mediate (referring to for example, Lu N Z, Shlaes TA, Cundlah C, Dziennis S E, Lyle R E, Bethea C L, " Ovarian steroid action on tryptophan hydroxylase protein and serotonin compared to localization of ovarian steroid receptors in midbrain of guinea pigs. " Endocrine 11:257-267, 1999).The pleiotropy of natural estrogen makes it can not be extensively and life-time service, because this can increase the risk of breast, uterus, ovary tissue hyperplasia.The discovery of estrogen receptor ER β provides a kind of more method of multi-selection oestrogenic hormon reagent that identifies, and described selective estrogen reagent not only has required antidepressant activity but also the alpha mediated proliferative effect of ER can not occur.Thereby, proved that the medicine with ER beta selective has potential curative effect in treating depression.
This area needs is the compound that not only can produce the active responding same with controversies in hormone replacement in the elderly (estrogen replacement therapy) but also there is no adverse side effect.Meanwhile, also need to bring into play to the different tissues of health the oestrogen-like hormone compound (estrogen-like compound) of selective effect.
US 2003/0220377 discloses some and can be used as benzazolyl compounds and their potential uses aspect the illness for the treatment of estrogen-mediated of estrogen agonist and antagonist.JP 2001-122855 discloses some and can be used for treating the selectively acting of osteoporosis in the benzazolyl compounds of erss.
Compound of the present invention is the part of estrogen receptor, therefore can be applied to treatment or prevent the multiple illness relevant to estrogen function.
Summary of the invention
The compound or its pharmaceutically useful ester, acid amides, solvate or the salt that the invention provides a kind of formula (I), comprise the salt of described ester or acid amides and the solvate of described ester, acid amides or salt,
R wherein
1be selected from halogen, cyano group, nitro, OR
a, N (R
b)
2,-C (O) C
1-4alkyl ,-SO
2c
1-4alkyl, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl, three halo C
1-6alkyl, halo C
2-6thiazolinyl, dihalo C
2-6thiazolinyl, three halo C
2-6thiazolinyl, cyano group C
1-6alkyl, C
1-4alkoxy C
1-6alkyl, C
3-8cycloalkyl, C
3-8cycloalkyl C
1-6alkyl, phenyl, phenmethyl and 5-10 unit heterocyclic radical, wherein said phenyl, phenmethyl or heterocyclic radical group can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from OR
a, halogen, cyano group, nitro ,-C (O) C
1-4alkyl, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl;
R
2be selected from cyano group, nitro, N (OH)
2,-CHO ,-CH=N-OH, optionally by 1-3 halogen atom, replaced-C (O) C
1-4alkyl ,-SO
2c
1-4alkyl ,-C (O) NH-OH ,-C (NH
2)=N-OH ,-C (CO
2h)=N-OH ,-C (NH
2)=NH ,-C (NH
2)=N-NH
2,-NH-C (NH
2)=NH ,-NH-C (O) NH
2,-N=C (NH-CH
2cH
2-NH-) ,-S-CN ,-S-C (NH
2)=NH ,-S-C (NH
2)=N-OH ,-CO
2h ,-CH (OH) CO
2h ,-C (O) N (R
c)
2,-SO
2c
1-6alkyl, SO
2n(R
c)
2,-C (O)-C (O)-NH
2,-CH
2nH-CONH
2,-SO
2oR
c,-C (O) CO
2h ,-CH
2sO
3h and 5-10 unit heterocyclic radical, wherein said heterocyclic radical group can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl;
R
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10in each independently selected from hydrogen, OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl;
Each R
aindependently selected from hydrogen, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, C
3-8cycloalkyl, C
3-8cycloalkyl C
1-6alkyl, phenyl, phenmethyl and 5-10 unit heterocyclic radical, each group is optionally replaced by 1-3 halogen atom; And
Each R
bindependently selected from hydrogen, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, C
3-8cycloalkyl, C
3-8cycloalkyl C
1-6alkyl, phenyl, phenmethyl and 5-10 unit heterocyclic radical, each group is optionally replaced by 1-3 halogen atom; And
Each R
cindependently selected from hydrogen and C
1-6alkyl.
The inventor is surprised to find that, compound of the present invention is the part of estrogen receptor.So compound of the present invention can be used for treatment or the prevention disease relevant to estrogen receptor activity.
Embodiment
Compound of the present invention can comprise chirality (asymmetric) center or whole molecule is chirality.Scope of the present invention comprises single steric isomer (enantiomer and diastereomer) and their mixture.
Compounds more of the present invention comprise one can be with (E) or oximido group that (Z) type oxime (oxime) isomeric forms exists.Scope of the present invention comprises single (E) and (Z) mixture of type oxime isomers and they.This specification sheets in the whole text in, shown oxime structure uses the key table with wavy line to show, this shows to exist individual isomer but its stereochemistry is unknown, or has the mixture of two kinds of isomer.
The invention provides the compound as estrogen receptor ligands.Term used herein " estrogen receptor ligands " is intended to contain any part (moiety) that can be combined with estrogen receptor.This part can be used as agonist (agonist), partial agonist (partial agonist), antagonist (antagonist) or partial antagonist (antagonist).This part can be mixed active ER beta selective or that show ER α and ER β.For example, this part both can be used as agonist or the partial agonist of ER β, can be used as again antagonist or the partial antagonist of ER α.Compound of the present invention is preferably the estrogen receptor ligands that shows ER beta selective agonism.
Work as R
1when representing heterocyclic group, this group can be saturated or undersaturated, and can comprise one or more oxygen, nitrogen and/or sulphur atom.Preferably 5 rings or 6 rings.In a preferred embodiment, it is 6 rings or particularly 5 rings, and preferably undersaturated, particularly aromatics.Applicable heterocyclic radical group comprises furyl (furyl), thienyl (thienyl), pyrryl (pyrrolyl), pyrrolinyl (pyrrolinyl), pyrrolidyl (pyrrolidinyl), oxazolyl (oxazolyl), isoxazolyl (isoxazolyl), thiazolyl (thiazolyl), isothiazolyl (isothiazolyl), imidazolyl (imidazolyl), imidazolinyl (imidazolinyl), imidazolidyl (imidazolidinyl), pyrazolyl (pyrazolyl), pyrazolinyl (pyrazolinyl), pyrazolidyl (pyrazolidinyl), pyridyl (pyridyl), morpholinyl (morpholinyl) and piperidyl (piperidyl), thienyl wherein, isothiazolyl, particularly isoxazolyl is particularly preferred.The preferred substituting group of heterocyclic radical group comprises 1-3,1 or 2 substituting group for example, and each substituting group is selected from OR
a, halogen, cyano group ,-C (O) C
1-4alkyl, C
1-4alkyl, C
2-4thiazolinyl, C
2-4alkynyl, halo C
1-4alkyl, dihalo C
1-4alkyl and three halo C
1-4alkyl.Particularly preferred substituting group is selected from halogen, cyano group, C
1-4alkyl (particularly methyl) ,-C (O) C
1-4alkyl and OR
a---R wherein
apreferably represent hydrogen atom or C
1-4alkyl.More particularly preferred substituting group is selected from halogen, cyano group and C
1-4alkyl (particularly methyl or ethyl).So, in a preferred embodiment, R
1by one of two methyl substituted above-mentioned groups, for example 3,5-dimethyl isoxazole-4-base, 2,4-dimethyl-thiene-3-yl-or 3,5-dimethyl isothiazole-4-base.
R
1during for phenyl, preferred substituting group comprises above-mentioned R
1those substituting groups during for heterocyclic radical group.
Work as R
2while representing heterocyclic radical group, this group can be for example above-mentioned R
1preferred group in one.
Except as otherwise noted, each R
apreferably independently selected from hydrogen, C
1-4alkyl, C
2-4thiazolinyl, C
2-4alkynyl, C
3-6cycloalkyl, phenyl and phenmethyl.Preferably, each R
arepresent independently hydrogen or C
1-4alkyl, particularly methyl.
Except as otherwise noted, each R
bpreferably independently selected from hydrogen and C
1-4alkyl, particularly methyl.
Except as otherwise noted, each R
cpreferably independently selected from hydrogen and C
1-4alkyl, particularly methyl.In one embodiment, each R
call represent hydrogen.
Preferably, R
1be selected from C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, phenyl or 5-10 unit heterocyclic radical, wherein said phenyl or heterocyclic radical group can be unsubstituted or be substituted as mentioned above.More preferably, R
1be selected from C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, phenyl or 5-10 unit heterocyclic radical, wherein said phenyl or heterocyclic radical group can be unsubstituted or by 1-2 substituting group replacement, each substituting group is independently selected from cyano group or C
1-6alkyl.Most preferably, R
1represent phenyl or 5-6 unit heterocyclic radical group, wherein said phenyl or heterocyclic radical group are replaced by 1-2 substituting group, and described substituting group is C
1-6alkyl.In a further preferred embodiment, R
1represent phenyl or 5 yuan of heterocyclic radical groups, wherein said phenyl or heterocyclic radical group are replaced by two substituting groups, and described substituting group is methyl.For example, R
1can be 2,5-3,5-dimethylphenyl, 3,5-dimethyl isoxazole-4-base, 2,4-dimethyl-thiene-3-yl-or 3,5-dimethyl isothiazole-4-base.
In one embodiment of the invention, R
2be selected from cyano group ,-CHO ,-CH=N-OH ,-C (O) NH-OH ,-C (NH
2)=N-OH ,-C (CO
2h)=N-OH ,-C (NH
2)=NH ,-C (NH
2)=N-NH
2,-NH-C (NH
2)=NH ,-NH-C (O) NH
2,-S-CN ,-S-C (NH
2)=NH ,-S-C (NH
2)=N-OH ,-CO
2h ,-CH (OH) CO
2h ,-C (O) N (R
c)
2, SO
2n(R
c)
2,-C (O)-C (O)-NH
2,-CH
2nH-CONH
2,-SO
2c
1-6alkyl ,-SO
2oR
c,-C (O) CO
2h ,-CH
2sO
3h and 5-6 unit heterocyclic radical, wherein said heterocyclic radical group can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl.In a preferred embodiment of the present invention, R
2represent cyano group ,-CH=N-OH ,-C (O) N (R
c)
2,-C (NH
2)=N-OH, SO
2n(R
c)
2,-SO
2c
1-6alkyl ,-SO
2oR
cor the 5-6 unit heterocyclic group that does not replace or replaced by 1-3 substituting group, each substituting group is independently selected from OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl.More preferably, R
2be selected from cyano group ,-CH=N-OH ,-C (O) N (R
c)
2,-C (NH
2)=N-OH, SO
2n(R
c)
2,-SO
2c
1-4alkyl and-SO
2oR
c.
In another embodiment of the invention, R
2be selected from cyano group, nitro, N (OH)
2,-CHO, optionally by 1-3 halogen atom, replaced-C (O) C
1-4alkyl ,-SO
2c
1-4alkyl ,-C (O) NH-OH ,-C (NH
2)=N-OH ,-C (CO
2h)=N-OH ,-C (NH
2)=NH ,-C (NH
2)=N-NH
2,-NH-C (NH
2)=NH ,-NH-C (O) NH
2,-N=C (NH-CH
2cH
2-NH-) ,-S-CN ,-S-C (NH
2)=NH ,-S-C (NH
2)=N-OH ,-CO
2h ,-CH (OH) CO
2h ,-C (O) N (R
c)
2,-SO
2c
1-6alkyl ,-C (O)-C (O)-NH
2,-CH
2nH-CONH
2,-SO
2oR
c,-C (O) CO
2h ,-CH
2sO
3h and 5-10 unit heterocyclic group, wherein said heterocyclic group can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl.In the present embodiment, R
2preferably represent cyano group ,-C (O) N (R
c)
2,-C (NH
2)=N-OH ,-SO
2c
1-6alkyl ,-SO
2oR
cor the first heterocyclic group of 5-6 unsubstituted or that replaced by 1-3 substituting group, wherein each substituting group is independently selected from OR
a, halogen, cyano group, nitro, C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, dihalo C
1-6alkyl and three halo C
1-6alkyl.In the present embodiment, more preferably, R
2be selected from cyano group ,-C (O) N (R
c)
2,-C (NH
2)=N-OH ,-SO
2c
1-4alkyl and-SO
2oR
c.
Preferably, R
2be selected from-C (NH
2)=N-OH or-C (O) N (R
c)
2, particularly-C (NH
2)=N-OH or C (O) NH
2, particularly-C (NH
2)=N-OH.
Preferably, R
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10be selected from separately hydrogen, OR
a, halogen, cyano group, C
1-4alkyl is methyl, halo C for example
1-4alkyl is chloro or fluoro methyl, dihalo C for example
1-4alkyl is dichloro or difluoromethyl for example, and three halo C
1-4alkyl is trichlorine or trifluoromethyl for example.Preferably, R
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10be selected from separately hydrogen, OH, halogen, cyano group, methyl or trifluoromethyl.Most preferably, R
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10represent independently of one another hydrogen and/or halogen, particularly chlorine, or fluorine especially.In especially preferred embodiment, R
3, R
4, R
5and R
6represent separately hydrogen.In another preferred embodiment, R
7, R
8, R
9and R
10represent separately hydrogen, and R
7, R
8, R
9and R
10in one or two represent halogen, fluorine particularly, R
7, R
8, R
9and R
10in remaining represents hydrogen.
The compound of formula (I) includes but not limited to the compound of specifically mentioning in the embodiment of the present application.
Other compounds of formula (I) include but not limited to following compound:
2-(2,5-dimethyl-1 hydrogen-pyrroles-1-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (carboximidamide),
2-(Isosorbide-5-Nitrae-dimethyl-1 hydrogen-pyrazoles-5-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(2,5-dimethyl pyrrolidine-1-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
N '-hydroxyl-3-(4-hydroxyphenyl)-2-(pyrrolidin-1-yl)-1H-indoles-1-azomethine acid amides,
The chloro-2-of 5-(3,5-dimethyl isoxazole-4-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(5-fluoro-2,4-dimethyl furan-3-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(5-chloro-2,4-dimethyl furan-3-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(1,3-dimethyl-1 hydrogen-pyrroles-2-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(Isosorbide-5-Nitrae-dimethyl-1 hydrogen-imidazoles-5-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(2,5-dimethyl-1 hydrogen-imidazoles-1-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides,
2-(5-fluoro-2,4-dimethyl furan-3-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide,
2-(5-chloro-2,4-dimethyl furan-3-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide,
2-(1,3-dimethyl-1 hydrogen-pyrroles-2-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide,
2-(Isosorbide-5-Nitrae-dimethyl-1 hydrogen-imidazoles-5-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide,
2-(2,5-dimethyl-1 hydrogen-imidazoles-1-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide,
Or their pharmaceutically useful ester, acid amides, solvate or salt, comprise the salt of described ester or acid amides and the solvate of described ester, acid amides or salt.
In the compound of above listed compound and embodiment, compound according to IUPAC by ACD Labs 8.0/name program(8.05 version) and/or by ISIS DRAW Autonom 2000 and/or ChemBioDraw Ultra(11.0 version) name.
Different according to the substituting group existing in formula I compound, described compound can form ester, acid amides, carbamate and/or salt.Wherein gegenion or related solvents are pharmaceutically useful salt and solvate for those to be applicable to the salt of medicinal formula (I) compound and solvate.Within but the salt that contains non-pharmaceutically useful gegenion or related solvents and solvate are also contained in scope of the present invention, for example,, as at preparation formula (I) compound and their pharmacologically acceptable salt, solvate with there is the intermediate in the derivative process of physiological function.Term " derivative with physiological function " refers to the chemical derivative having with formula (I) compound of the identical physiological function of free cpds of formula (I), for example, by transforming in vivo.Ester, acid amides and carbamate are all the examples with physiological function derivative.
Acceptable acid addition salts in the present invention comprises the salt forming with the acid of organic or inorganic or alkali.Particularly, the acceptable acid addition salts forming with acid of the present invention comprises the salt forming with mineral acid, strong organic carboxyl acid or organic sulfonic acid, described strong organic carboxyl acid is the alkane carboxylic acid (alkanecarboxylic acid) of 1-4 carbon atom unsubstituted or that replaced by halogen for example for example, saturated or undersaturated dicarboxylic acid (dicarboxylic acid) for example, for example hydroxycarboxylic acid, for example amino acid; Described organic sulfonic acid is such as unsubstituted or by (the C replacing such as halogen etc.
1-C
4)-alkyl-or aryl-sulfonic acid.Pharmaceutically useful acid salt comprises the acid salt being formed by following acid: hydrochloric acid, Hydrogen bromide, sulfuric acid, nitric acid, citric acid, tartrate, acetic acid, phosphoric acid, lactic acid, pyruvic acid, acetic acid, trifluoroacetic acid, succsinic acid, perchloric acid, FUMARIC ACID TECH GRADE, toxilic acid, oxyacetic acid, lactic acid, Whitfield's ointment, oxaloacetic acid, methylsulfonic acid, ethyl sulfonic acid, tosic acid, formic acid, phenylformic acid, propanedioic acid, naphthalene-2-sulfonic acid, Phenylsulfonic acid, hydroxyethylsulfonic acid, xitix, oxysuccinic acid, phthalic acid, aspartic acid, L-glutamic acid, Methionin and arginine.Other acid is oxalic acid for example, although itself is not pharmaceutically acceptable, can be used as the intermediate use that obtains the compounds of this invention or their pharmaceutically useful acid salt.
Pharmaceutically useful alkali salt comprises for example for example calcium salt and magnesium salts of sylvite and sodium salt, alkaline earth salt of ammonium salt, an alkali metal salt, and the salt that forms of organic bases for example dicyclohexyl amine, N-methyl D-glucosamine (glucomine), morpholine, thiomorpholine, piperidines, tetramethyleneimine, single low-grade alkylamine, two low-grade alkylamines or three low-grade alkylamines, for example ethamine, tert-butylamine, diethylamine, Diisopropylamine, triethylamine, Tributylamine or dimethyl propylamine, or monohydroxy, dihydroxyl or trihydroxy-low-alkylamine, for example monoethanolamine, diethanolamine or trolamine.And, can also form corresponding inner salt.
Formula (I) compound can have the proper group that can be transformed into ester, acid amides or carbamate.Thereby the typical ester and the amide group that are formed by acid groups in the compound of formula (I) comprise :-COOR
b,-CONR
b 2,-SO
2oR
bor-SO
2n(R
b)
2; And in formula I compound by-OH or-NHR
bgroup form typical ester, acid amides and carbamate groups comprise :-OC (O) R
b,-NR
bc (O) R
b,-NR
bcO
2r
b,-OSO
2r
bwith-NR
bsO
2r
b, R wherein
bthere is one of implication given above.
The technician of organic chemistry filed will appreciate that, when many organic compound can react with them, solvent wherein of living in or they form mixture from wherein forming the solvent of precipitation or crystallization.This mixture is called " solvate ".For example, be called " hydrate " with the mixture of water formation.
The compound that can transform into above-mentioned formula (I) compound or its active metabolite or residue after giving receptor is called " prodrug ".For example, prodrug can be by changing into its medicative activity form such as the mode such as be hydrolyzed in blood in vivo.Pharmaceutically useful prodrug is at T.Higuchi and V.Stella, Prodrugs as Novel Delivery Systems, Vol.14 of the A.C.S.Symposium Series (1976)); " Design of Prodrugs " ed.H.Bundgaard, Elsevier, 1985; And at Edward B.Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, in 1987, describe to some extent, described document is included in herein by reference.
Unless separately there is restriction under particular case, following definitions is applicable to this specification term used.
Term used herein " alkyl " represents the saturated hydrocarbyl of straight chain and side chain.The example of alkyl comprises methyl, ethyl, n-propyl, sec.-propyl, normal-butyl, the tertiary butyl, isobutyl-, sec-butyl, amyl group and hexyl.In non-branched-chain alkyl, preferable methyl, ethyl, n-propyl, sec.-propyl, normal-butyl and n-pentyl.In branched-chain alkyl, that may mention has sec.-propyl, the tertiary butyl, isobutyl-, 1-ethyl propyl and a 1-ethyl-butyl.
Term used herein " alkoxyl group " represents O-alkyl, and wherein " alkyl " as mentioned above.The example of alkoxyl group comprises methoxyl group and oxyethyl group.Other example comprises propoxy-and butoxy.
Term used herein " thiazolinyl " represents the straight chain and the side chain unsaturated alkyl that contain at least one carbon-carbon double bond.The example of thiazolinyl comprises vinyl, propenyl, butenyl, pentenyl and hexenyl.Preferred thiazolinyl comprises vinyl, 1-propenyl, 2-propenyl and but-2-ene base.
Term used herein " alkynyl " represents the straight chain and the side chain unsaturated alkyl that contain at least one carbon carbon triple bond.The example of alkynyl comprises ethynyl, proyl, butynyl, pentynyl and hexin base.Preferred alkynyl comprises ethynyl, 1-proyl and 2-propynyl.
Term used herein " cycloalkyl " represents the saturated group of ring system.Cycloalkyl can be monocycle or two rings.Bicyclic groups can be for example for condensing or bridge joint.The example of the cycloalkyl of monocycle comprises cyclopropane, tetramethylene and pentamethylene.Other examples of the cycloalkyl of monocycle have hexanaphthene, suberane and cyclooctane.The example of the cycloalkyl of two rings comprises two rings [2.2.1] heptan-2-base.Preferably cycloalkyl is the cycloalkyl of monocycle.
Term used herein " aryl " represents monocycle or bicyclic aromatic carbocyclic ring.The example of aryl comprises phenyl and naphthyl.Naphthyl can pass through 1 or 2 linking groups.In aryl bicyclic, one of them ring can be for example fractional saturation.The example of this class group comprises indanyl (indanyl) and tetralyl.Particularly, term C used herein
5-10aryl is illustrated in and in monocycle or aryl bicyclic, contains 5-10 carbon atom.Especially preferred C
5-10aryl is phenyl.
Term used herein " halogen " represents fluorine, chlorine, bromine or iodine.Especially preferred is fluorine, chlorine and bromine.
Term used herein " haloalkyl " represents to have the alkyl of halogenic substituent, and the implication of term " alkyl " and " halogen " is interpreted as having implication as mentioned above.Similarly, term " dihalo alkyl " represents the alkyl of two halogenic substituents, and term " tri haloalkyl " indicates the alkyl of three halogenic substituents.The example of haloalkyl comprises fluoro methyl, chloro methyl, bromomethyl, fluoro methyl, fluoro propyl group and fluoro butyl; The example of dihalo alkyl comprises difluoromethyl and two fluoro ethyls; The example of tri haloalkyl comprises trifluoromethyl and trifluoroethyl.
Term used herein " heterocyclic radical " represents that wherein 1-3 carbon atom substituted aromatics or the non-aromatic carbon ring group forming by one or more heteroatomss independently selected from nitrogen, oxygen or sulphur.Heterocyclic group can be for example monocycle or bicyclic groups.In bicyclic heterocycles group, each ring or only have one of them ring on can have one or more heteroatoms.Heteroatoms can be for example Sauerstoffatom or nitrogen-atoms.The heterocyclic group that contains suitable nitrogen-atoms comprises corresponding oxynitride.
The example of the non-aromatic heterocyclic group of monocycle (also referred to as the heterocycloalkyl ring of monocycle) comprises aziridinyl (aziridinyl), azelidinyl (azetidinyl), pyrrolidyl (pyrrolidinyl), imidazolidyl (imidazolidinyl), pyrazolidyl (pyrazolidinyl), piperidyl (piperidinyl), piperazinyl (piperazinyl), tetrahydrofuran base (tetrahydrofuranyl), THP trtrahydropyranyl (tetrahydropyranyl), morpholinyl (morpholinyl), thio-morpholinyl (thiomorpholinyl) and azepan base (azepanyl).
One of them ring is that the example of the bicyclic heterocycles group of non-aromatic ring comprises dihydro benzo furyl (dihydro benzofuranyl), indanyl (indanyl), indolinyl (indolinyl), iso-dihydro-indole-group (isoindolinyl), tetrahydro isoquinolyl (tetrahydroisoquinolinyl), tetrahydric quinoline group (tetrahydroquinolyl) and benzo-aza suberyl (benzoazepanyl).
The example of monocyclic aromatic heterocyclic group (also referred to as bicyclic heteroaryl group) comprises furyl (furanyl), thienyl (thienyl), pyrryl (pyrrolyl), oxazolyl (oxazolyl), thiazolyl (thiazolyl), imidazolyl (imidazolyl), oxadiazolyl (oxadiazolyl), thiadiazolyl group (thiadiazolyl), pyridyl (pyridyl), triazolyl (triazolyl), triazinyl (triazinyl), pyridazinyl (pyridazyl), isothiazolyl (isothiazolyl), isoxazolyl (isoxazolyl), pyrazinyl (pyrazinyl), pyrazolyl (pyrazolyl) and pyrimidyl (pyrimidinyl).
The example of bicyclic aromatic heterocyclic group (also referred to as bicyclic heteroaryl group) comprises quinoxalinyl (quinoxalinyl), quinazolyl (quinazolinyl), pyrido-pyrazine base (pyridopyrazinyl), benzoxazolyl (benzoxazolyl), benzo thiophenyl (benzothiophenyl), benzimidazolyl-(benzimidazolyl), 1, 5-phthalazinyl (naphthyridinyl), quinolyl (quinolinyl), benzofuryl (benzofuranyl), indyl (indolyl), benzothiazole (benzothiazolyl), oxazolyl [4, 5-b] pyridyl (oxazolyl[4, 5-b] pyridiyl), Pyridopyrimidine base (pyridopyrimidinyl), isoquinolyl (isoquinolinyl) and Ben Bing bis-oxazole (benzodroxazole).
The example of preferred heterocyclic group comprises piperidyl (piperidinyl), tetrahydrofuran base (tetrahydrofuranyl), THP trtrahydropyranyl (tetrahydropyranyl), pyridyl (pyridyl), pyrimidyl (pyrimidinyl) and indyl.Preferred heterocyclic group also comprises thienyl (thienyl), thiazolyl (thiazolyl), furyl (furanyl), pyrazolyl (pyrazolyl), pyrryl (pyrrolyl), isoxazolyl (isoxazolyl) and imidazolyl (imidazolyl).
Cycloalkyl-alkyl that term used herein " cycloalkylalkyl " expression is connected by alkyl-, wherein " cycloalkyl " and " alkyl " is interpreted as having implication as above.
As mentioned above, compound of the present invention has estrogen receptor ligands activity.Compound of the present invention has estrogenic agents activity, can be agonist, partial agonist, antagonist or the partial antagonist of estrogen receptor.Especially preferred the compounds of this invention has agonist or the partial agonist activity of ER β.Preferred this compounds is the selective agonist of erss (ER β).
Thus, the compound in the present invention can be used for the treatment of disease or the illness that estrogen receptor activity is relevant.Particularly, as the compounds of this invention of estrogen receptor agonist or partial agonist, can be used for treating selective estrogen receptor agonist or partial agonist is specified available disease or illness.As the antagonist of estrogen receptor or the compounds of this invention of partial antagonist can be used for treating selective estrogen receptor antagonist or partial antagonist is specified available disease or illness.
Agonist or partial agonist are specified available clinical disease and include but not limited to: bone loss (bone loss), fracture (bone fracture), osteoporosis, cartilage degeneration (cartilage degeneration), endometriosis (endometriosis), leiomyoma of uterus (uterine fibroid disease), hot flush (hot flush), LDL-C level rising (increased levels of LDL cholesterol), cardiovascular disorder (cardiovascular disease), Cognitive function damage (impairment of cognitive functioning), brain degenerative disease (cerebral degenerative disorder), restenosis (restenosis), gynecomastia (gynecomastia), vascular smooth muscle cell curing (vascular smooth muscle cell proliferation), obesity (obesity), incontinence (incontinence), anxiety (anxiety), depressed (depression), autoimmune disorder, inflammation (inflammation), inflammatory bowel (IBD), irritable bowel syndrome (IBS), sexual dysfunction (sexual dysfunction), hypertension (hypertension), retinal degeneration (retinal degeneration), and lung, colon, breast, uterus and carcinoma of prostate, and/or the relevant illness of estrogen function.
Compound in the present invention can or be treated following illness specifically for prevention: bone loss, fracture, osteoporosis, cartilage degeneration, endometriosis, leiomyoma of uterus, hot flush, LDL-C level raises, cardiovascular disorder, Cognitive function damage, the mild cognitive impairment that age is relevant, brain degenerative disease, restenosis, gynecomastia, vascular smooth muscle cell curing, obesity, incontinence, anxiety, depressed, climacteric depressed (perimenopausal depression), postpartum depression (post-partum depression), premenstrua syndromes (premenstrual syndrome), manic depression (manic depression), dull-witted (dementia), compulsive behavior (obsessive compulsive behavior), attention deficit disorder (attention deficit disorder), the many moving attention deficit disorders (attention deficit hyperactivity disorder) of companion, somnopathy (sleep disorders), irritability (irritability), impulsion (impulsivity), indignation management (anger management), dysaudia (hearing disorder), multiple sclerosis (multiple sclerosis), Parkinson's disease (Parkinson ' s disease), alzheimer's disease (Alzheimer ' s disease), Huntington's disease (Huntington ' s disease), amyotrophic lateral sclerosis (amyotrophic lateral sclerosis), Spinal injury (spinal cord injury), apoplexy (stroke), autoimmune disorder, inflammation, IBD, IBS, sexual dysfunction, hypertension, retinal degeneration, and lung cancer, colorectal carcinoma, mammary cancer, uterus carcinoma, prostate cancer and the bile duct cancer form that is called as cholangiocarcinoma (cholangiocarcinoma).Compound of the present invention also can be also specifically for treatment or prevent following illness: benign prostate hyperplasia (benign prostatic hyperplasia), lower urinary tract syndromes (lower urinary tract symptom), bladder hyperactivity hyperkinesia (overactive bladder), interstitial cystitis (interstitial cystitis), bladder pain syndromes (painful bladder symptom), vaginal atrophy (vaginal atrophy), wound healing (wound healing), chronic pain (chronic pain), Sepsis (sepsis), inflammatory neurodynia (inflammatory and neuropathic pain), ovarian cancer (ovarian cancer), melanoma (melanoma) and lymphoma (lymphoma) (B cell lymphoma, t cell lymphoma).
Medicine of the present invention also can with the Drug combination of known contracting (vasomotor) symptom of can induction of vascular relaxing, for following purposes: with selective estrogen receptor modulators (SERM) for example tamoxifen (tamoxifen) combine and be used for the treatment of mammary cancer, combine with raloxifene and be used for the treatment of and/or preventing osteoporosis disease, thereby alleviate the vasomotor symptoms that SERM induces; Combine with aromatase inhibitor and be used for the treatment of mammary cancer or endometriosis, to alleviate the vasomotor symptoms of aromatase inhibitor induction; And for having carried out the prostate cancer patient of male sex hormone castration (androgen deprivation).
In one embodiment of the invention, compound of the present invention can be used for treatment or prevention of depression, study on perimenopausal depressive disorder, post-natal depression, premenstrual syndrome and manic dysthymia disorders.
The treatment of male sex's hot flush or prevention are preferred for to the patient who causes male sex hormone disappearance because of carcinoma of prostate treatment.
Term " dysthymia disorders " includes but not limited to the mood disorder that serious Depressive, dysthymic disorder, two-way type obstacle, circulation affective disorders, general curative situation cause, mood disorder, seasonal affective disorder (SAD), postpartum depression and the premenstrual dysphoric disorder of material induction.
The present invention also provides the method for the treatment of or preventing the illness of Mediated by Estrogen Receptor in Mammals, and described method comprises the compound of the present invention that gives described Mammals treatment significant quantity.The clinical disease of the Mediated by Estrogen Receptor that can treat by the inventive method is listed those illnesss above preferably.
The present invention also provides the purposes of compound of the present invention for the manufacture of the medicament for the treatment of or prevention Mediated by Estrogen Receptor illness.The clinical disease of the Mediated by Estrogen Receptor that can treat by the inventive method is listed those illnesss above preferably.
The amount that reaches the activeconstituents of result for the treatment of certainly can be along with particular compound, route of administration, the experimenter that treating (comprise build, species, age, body weight, sex, experimenter's medical conditions and experimenter's hepatic and renal function), and the concrete illness for the treatment of or disease and severity thereof and change.Physician, animal doctor or the clinician with ordinary skill level can easily determine to be needed prevention, antagonism or stops the medicine effective quantity of illness process and output prescription.
When doing the used time for generation of above-mentioned, adult's oral dosage of the present invention should be between the about 0.01mg of every kg body weight every day (mg/kg/ day) to approximately 100mg/kg/ day, preferably 0.01-10mg/kg/ day, most preferably 0.1-5.0mg/kg/ day.When oral, described composition preferably provides with tablet form, or provide with the discrete unit containing 0.01,0.05,0.1,0.5,1.0,2.5,5.0,10.0,15.0,25.0,50.0,100 and 500 milligram of activeconstituents, for carrying out symptom adjusting to giving patient's to be treated dosage.Medicament is conventionally containing the extremely about 500mg activeconstituents of 0.01mg of having an appointment, and preferred about 1mg is to about 100mg activeconstituents.During intravenous injection, most preferred dosage range is approximately 0.1 to about 10mg/kg/min when constant rate of speed infusion.The compounds of this invention can be advantageously with single dose administration every day, or every TDD can be divided into the dosed administration of every day twice, three times or four times.In addition, preferred compound of the present invention can be by transporting instrument with form administration in nose or applying transdermal patch form well known to those of ordinary skill in the art by through skin administration in the suitable nose of topical application.When sending delivery system form administration through skin, described dosed administration certainly should be for continuing medication in whole dosage, rather than discontinuity administration.
Although can give separately activeconstituents, preferably it is present in pharmaceutical preparation or composition.Correspondingly, the invention provides a kind of pharmaceutical preparation that contains the compounds of this invention and pharmaceutically useful thinner, vehicle or carrier (" carrier " material is made in common name herein).Pharmaceutical composition of the present invention can adopt the form of following pharmaceutical preparation.
Pharmaceutical preparation of the present invention comprises and is suitable for oral, parenteral (comprising subcutaneous injection, intradermal injection, intramuscularly, intravenous injection (injecting or infusion) and intra-articular injection), sucks (comprising molecule pulvis or the aerosol that can be produced by various types of metered dose pressurised aerosols), atomizer or insufflator, rectum, intraperitoneal or part (comprise skin, containing clothes, hypogloeeis and intraocular) administration, but optimal approach can be determined according to for example receptor's disease or illness.
Described preparation can exist with unit dosage form easily, also can prepare by known method in pharmaceutical field.All methods all comprise mixes activeconstituents with the carrier that forms one or more ancillary components.Generally speaking, by activeconstituents is mixed with liquid carrier and/or the direct homogeneous of powder solid carrier, and, if desired product is made to needed preparation shape.
Be applicable to the preparation of the present invention form existence as follows of oral administration: discrete units, for example capsule, cachet, pill or tablet, the activeconstituents that each unit contains predetermined amount; Powder or particle; Solution in water-based or non-aqueous liquid or suspension, for example elixir (elixir), tincture (tincture), suspension or syrup; Or oil-in-water liquid emulsion or water-in-oil liquid emulsion.Described activeconstituents can be also bolus, electuary or paste form.
Tablet can be made by compacting or molding, optionally uses one or more ancillary components.Compressed tablet can for example, by suitable machine, the activeconstituents of free-flowing form (powder or particle form) being suppressed and is prepared from, optional and tackiness agent, lubricant, inert diluent, lubricant, tensio-active agent or dispersant.Moulded tablet can be made by the mixture with the moistening powdered compounds of inert liquid diluent being carried out to molding in suitable machine.Tablet optionally carries out dressing or mint-mark, and can be mixed with slow release or the form of release of active ingredients controllably.Compound of the present invention can be for example to be suitable for quick-acting release or to extend the form administration discharging.Quick-acting release or extend to discharge can be by using the suitable pharmaceutical composition that contains the compounds of this invention to realize, or particularly with regard to extending and discharging, can be by using devices such as hypodermic implant or osmotic pump to realize.Compound of the present invention also can liposome form administration.
For oral exemplified composition, comprising can be containing the suspension of following composition, for example for the Microcrystalline Cellulose of packing volume, as the Lalgine of suspending agent or sodium alginate, as the methylcellulose gum of tackifier, and sweetener or seasonings for example as known in the art those; And can be containing the fast-release tablet of following composition, for example Microcrystalline Cellulose, Si Liaodengji dicalcium phosphate feed grade, starch, Magnesium Stearate, calcium sulfate, sorbyl alcohol, glucose and/or lactose and/or other vehicle, tackiness agent, expanding material, disintegrating agent, thinner and lubricant, for example known in the art those.Suitable tackiness agent comprises that starch, gelatin, natural sugar such as glucose or beta lactose, corn sweetener, natural or synthetical glue are as gum arabic (acacia), Tragacanth (tragacanth) or sodium alginate, carboxymethyl cellulose, polyoxyethylene glycol and wax class etc.Disintegrating agent includes but not limited to starch, methylcellulose gum, agar, wilkinite (bentonite) and xanthocyte gum (xanthan gum) etc.The compound of formula (I) also can pass through orally administering with hypogloeeis and/or containing taking mode.Molded tablet, compressed tablet or lyophilize sheet are operable exemplary form.The composition of example also comprises for example, composition with instant thinner (N.F,USP MANNITOL, lactose, sucrose and/or cyclodextrin) preparation the compounds of this invention.This class preparation also can contain high molecular vehicle, for example Mierocrystalline cellulose (Avicel) or polyoxyethylene glycol (PEG).This class preparation also can be containing the vehicle of helpful increase mucous membrane adhesive ability, such as hydroxypropylcellulose (HPC), HPMC (HPMC), Xylo-Mucine (SCMC), copolymer-maleic anhydride (such as Gantrez etc.), and the reagent that can control release, such as acrylic copolymer (such as carbomer 934 etc.).For manufacture and easy to use, also can add lubricant, glidant, seasonings, toner and stablizer.Lubricant for these formulations comprises sodium oleate, sodium stearate, Magnesium Stearate, Sodium Benzoate, sodium-acetate and sodium-chlor etc.For the oral administration of liquid form, oral pharmaceutical composition can be combined use with any oral, avirulent, pharmaceutically useful inert support (such as ethanol, G & W etc.).
Compound in the present invention also can send delivery system administration by liposome, for example small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.Liposome can---DPPC, phosphatidylethanolamine (kephalin) or phosphatidylcholine (lecithin)---be formed by multiple phosphide.
The preparation of administered parenterally comprises water-based or the non-aqueous aseptic parenteral solution that can contain following composition: antioxidant, buffer reagent, fungistat and make preparation and solute that target recipient blood etc. oozes; And can suspending agent-containing and water-based or the non-aqueous sterile suspensions of thickening material.Described preparation can be single dose or multi-dose container form, and for example the peace of sealing is cutd open and bottle, and can under lyophilize (freeze-drying) condition, store, and only need to add before use sterile liquid carrier such as salt solution or water for injection.Interim injection solution and suspension can with aseptic powder, particle and above the tablet of described kind make.The exemplified composition of administered parenterally comprises Injectable solution or the suspension that can contain following component: thinner or solvent that for example suitable nontoxic parenteral can be used, N.F,USP MANNITOL, 1 for example, 3-butyleneglycol, water, ringer's solution, isotonic sodium chlorrde solution or other applicable dispersion agent or wetting agent and suspending agent, comprise synthetic monoglyceride or triglyceride, and lipid acid comprises oleic acid or Cremaphor.
The solution that comprises salt solution form for the exemplified composition of intranasal administration, aerosol delivery or inhalation, it can contain phenylcarbinol for example or other applicable sanitas, strengthen absorption enhancer and/or other solubilizing agent or the dispersion agent of bioavailability, for example known in the art those.
Rectal administration preparation can be the suppository form containing common carrier, and described common carrier is theobroma oil, synthetic glyceride or polyoxyethylene glycol for example.Examples of such carriers is solid conventionally at normal temperatures, thereby still can liquefy and/or dissolve in enteric cavity, discharges described medicine.
The preparation of oral cavity local medication's (for example containing clothes or hypogloeeis) be included in (such as sucrose and gum arabic or Tragacanth) seasonings matrix containing the dragee of activeconstituents and in (such as gelatin, glycerine or sucrose and gum arabic) matrix containing the pastille of activeconstituents.The exemplary composition of topical comprises the topical carrier such as Plastibase (with the mineral oil of polyethylene gel).
Preferred unit dose formulations is the preparation of the activeconstituents that contains effective dose as mentioned above or its suitable part amount.
Should be understood that except the above-mentioned component of specifically mentioning, preparation of the present invention can also comprise other conventional reagent of this area relevant with object preparation type, for example, be applicable to other oral reagent and can comprise seasonings.
Compound of the present invention both can be used as activeconstituents unique in medicament, also can combine use with one or more other active agents.Described other active agents can be other compound of the present invention, or they can be different healing potions, for example thymoleptic, anxiolytic, antipsychotic drug, can be used for prevention or treat osteoporotic medicine, can be used for prevention or treatment cancer medicine or other medicines active substance.For example, compound of the present invention can with other medicaments of significant quantity Combined Preparation effectively, described other medicaments are thymoleptic, anxiolytic, antipsychotic drug, organic diphosphonic acid salt or cathepsin K (cathepsin K) inhibitor for example.In a preferred embodiment, compound of the present invention can with the thymoleptic of significant quantity Combined Preparation effectively.The limiting examples of thymoleptic comprises noradrenaline reuptake inhibitor (noradrenaline reuptake inhibitor, NRI), selectivity serotonin reuptake inhibithors (selective serotonin reuptake inhibitor), oxidase inhibitor (monoamine oxidase inhibitor), tricyclics (tricyclic antidepressant, TCA), Dopamine HCL reuptake inhibithors (dopamine reuptake inhibitor, DRI), opioid (opioid), selectivity serotonin is absorption enhancer (selective seretonic reuptake enhancer) again, tetracyclic antidepressant (tetracyclic antidepressant), monoamine oxidase reversible inhibitor (reversible inhibitor of monoamine oxidase), Melatonin agonist (melatonin agonist), serotonin and noradrenaline reuptake inhibitor (serotonin and noradrenaline reuptake inhibitor, SNRI), Corticotropin releasing factor antagonists (corticotropin releasing factor antagonist), alpha-adrenergic aceptor antagonist (α-adrenoreceptor antagonist), 5HT1 α receptor stimulant and antagonist (5HT1 α receptor agonist and antagonist), lithium and atypical antipsychotic agents (atypical anti-psychotics).The example of SSRI class antidepressive comprises fluoxetine (Fluoxetine) and Sertraline (Sertraline); The example of SNRI class antidepressive comprises Venlafaxine (Venlafaxine), citalopram (Citalopram), paroxetine (Paroxetine), escitalopram (Escitalopram), fluvoxamine (Fluvoxamine); The example of SNRI class antidepressive comprises duloxetine (Duloxetine); The example of DRI and NRI class antidepressive comprises Wellbutrin (Bupropion); The example of TCA class antidepressive comprises amitriptyline (Amitriptyline) and dosulepin (Dothiepin) (dothiepin (Dosulepin)).The example of atypical antipsychotic agents comprises: leoponex (Clozapine), olanzapine (Olanzapine), risperidone (Risperidone), Quetiapine (Quetiapine), Ziprasidone (Ziprasidone) and Dopamine HCL partial agonist.The non-limitative example of anxiolytic comprises Benzodiazepines (benzodiazepine) and non-benzene (also) diazepine (non-benzodiazapine).The example of Benzodiazepines comprises lorazepam (lorazepam), alprazolam (alprazolam) and diazepam (diazepam).The example of non-Benzodiazepines comprises buspirone (Buspirone) (Buspar
), barbiturates (barbiturate) and meprobamate (meprobamate).Can combine and use one or more those other thymoleptic.
Tamoxifen (tamoxifene) or aromatase inhibitor that the example of anticarcinogen is used while comprising treatment mammary cancer.
When concrete treatment induction hot flush, compound of the present invention can be combined use with the medicament of this treatment.The limiting examples of this class combination therapy therapy comprises: compound of the present invention is combined with the tamoxifen for the treatment of mammary cancer, compound of the present invention is combined with the aromatase inhibitor for the treatment of mammary cancer or compound of the present invention is combined with the raloxifene for the treatment of osteoporosis.
The limiting examples of above-mentioned organic diphosphonic acid salt comprises: Alendronate (adendronate), clodronate (clodronate), etidronate (etidronate), ibandronate (ibandronate), incadronate (incadronate), YM 529 (minodronate), how to found phosphoric acid salt (neridronate), risedronate (risedronate), pyrrole profit phosphonate (piridronate), pamldronate (pamidronate), Tiludronate (tiludronate), zoledronate (zoledronate) and its pharmaceutically useful salt or ester or its mixture.Preferred organic diphosphonic acid salt comprises Alendronate (alendronate) and its pharmaceutically useful salt and mixture.Monosodium alendronate trihydrate (alendronate monosodium trihydrate) most preferably.
The exact dosage desired of described diphosphonate according to oral usefulness, Mammals or the people's of dosage regimen, concrete selected di 2 ethylhexyl phosphonic acid age, build, sex and physical appearance, the character of disease to be treated and severity and other relevant medical science or physiologic factor etc. determine.So accurate pharmacy effective dose cannot be predetermined, but it can easily be determined by nursing staff or clinicist.Can determine suitable amount by conventional animal model test and mankind's clinical study.On the whole, the appropriate amount of selected diphosphonate makes to reach the effect that suppresses bone resorption, that is to say the diphosphonate of the amount that can suppress bone resorption.Concerning the mankind, effective oral dosage of diphosphonate is generally approximately 1.5 to approximately 6000 μ g/kg body weight, preferably approximately 10 to approximately 2000 μ g/kg body weight.
For the human oral composition containing Alendronate, its pharmacologically acceptable salt or its pharmaceutically acceptable derivative, unitary dose generally comprises the about 140mg Alendronate in clinic effect of alendronate effective weight (in corresponding acid) about 8.75mg-.
Compound of the present invention can be used for the treatment of with other Drug combination of estrogen-mediated illness.Each component of this class combination medicine form can be in therapeutic process different time administration or in the administration simultaneously of the cooperative programs with that disperse or single respectively.So the present invention is understood to include all time or this class scheme of alternating treatment, term " administration (administering) " is also correspondingly by this understanding.Should be understood that the scope of cooperative programs that compound of the present invention and other are used for the treatment of the medicine of estrogen-mediated illness has contained the form that any and any pharmaceutical composition that is used for the treatment of estrogen function relative disease is combined in principle.
When combining use with compound of the present invention, above-mentioned other treatment reagent can for example be used according to the consumption described in Physicians ' Desk Reference (PDR) or the amount of being determined by those of ordinary skills.
When compound of the present invention is combined with one or more other treatment reagent while using, no matter simultaneously or be used to order administration, all preferred following blending ratio and dosage range:
When combining use with thymoleptic, anxiolytic, antipsychotic drug, organic diphosphonic acid salt or cathepsin K inhibitor, the compound of formula (I) can the ratio use to about 1:10 with about 10:1 with described another reagent.
The compound of the invention described above also can optionally be used as the diagnostic medicine of the disease that diagnosis is relevant to estrogen receptor dysfunction with the form of mark.For example this compound can be radiolabeled form.
The compound of the invention described above also can be optionally used as reference compound with the form of mark for looking for the method for other estrogen receptor agonists, partial agonist, antagonist or partial antagonist.Therefore, the invention provides a kind of method of finding estrogen receptor ligands, it comprise use compound of the present invention or through the compounds of this invention of mark pattern as reference compound.For example, the method can comprise a CBA, wherein the compound in the present invention and estrogen receptor keying action are combined the compound of feature and are declined because existing another kind to have estrogen receptor, for example, have estrogen receptor described in and have than the stronger estrogen receptor of target compound of the present invention in conjunction with feature in conjunction with the another kind of compound of feature.
Those skilled in the art can design the synthetic route of many compounds of this invention, and the present invention is not subject to the restriction of following possible synthetic route.In document, there are many methods for the synthesis of benzazolyl compounds, for example: Indoles Part One, W.J.Houlihan (ed.), 1972; Indoles, Sundberg, R.J., 1996; Heterocyclic Chemistry, Joule, J.A.; Mills, K.2000; Chem.Rev., 2005,105,2873-2920; Org.Lett.2006,8,5919-5922; Bioorg.Med.Chem.Lett., 2007,17,902-906; US 2003/0220377; JP 2001-122855; And Chem.Pharm.Bull., 2007,55 (2), 328-333.Below exemplarily show some possible synthetic routes.If suitable, the compounds of this invention of any initial generation can change into by known method another kind of compound of the present invention.
Universal method I
Following universal method can be for the preparation of R
2for cyano group ,-C (NH
2)=NOH or-C (O) NH
2the compound of formula (I).
(a) 4-methoxyphenyl boric acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(b) salt of wormwood, methyl alcohol;
(c) NBS, methylene dichloride;
(d) R
1-boric acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(e) 2,2-pair-(4-cyanato-phenyl) propane, Et
3n, methyl-sulphoxide;
(f) NaH, 2,2-pair-(4-cyanato-phenyl) propane, THF;
(g) BBr
3, methylene dichloride;
(h) oxammonium hydrochloride, NaOMe, methyl alcohol;
(i) NH
2oH, methyl-sulphoxide;
(j)NH
2OH,DCM;
(k) NH
2oH, methyl alcohol
Universal method I shown in above-mentioned reaction scheme is synthesizing for embodiment 1,2,3,5,7,10-12 and 16-23.The total Test details that is applicable to each step in the universal method of final compound in synthetic these embodiment has description in embodiment 1-3.
Universal method II
Following universal method can be for the preparation of R
2for-SO
2n(R
c)
2formula (I) compound.
(a)(R
c)
2NSO
2Cl,NaH,DMF;(b)BF
3·SMe
2,DCM
Universal method II shown in above-mentioned reaction scheme is synthesizing for embodiment 4 and 6.The total Test details that is applicable to each step in the universal method of final compound in synthetic these embodiment has description in embodiment 4.
Universal method III
Following universal method can be for the preparation of R
2for CHO or-formula (I) compound of CH=NOH.
(a)DIBAH,DCM;
(b) oxammonium hydrochloride, pyridine, methyl alcohol;
Universal method III shown in above-mentioned reaction scheme is synthetic for embodiment's 5.The total Test details that is applicable to each step in the universal method of final compound in synthetic this embodiment all has description in embodiment 5.
Universal method IV
Following universal method can be for the preparation of R
2for-C (O) NH (R
c) formula (I) compound.
(a)NCOR
c,DMF;(b)BF
3·SMe
2,CH
2Cl
2
Universal method IV shown in above-mentioned reaction scheme is synthetic for embodiment 8,9,13,14 and 15.The total Test details that is applicable to each step in the universal method of final compound in synthetic these embodiment has description in embodiment 8.
Universal method V
Following universal method can be used to prepare R
2for cyano group ,-C (NH
2)=NOH or-C (O) NH
2formula (I) in compound.
(a) NaH, 2,2-pair-(4-cyanato-phenyl) propane, THF;
(b) R
1-boric acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(c) BF
3.SMe
2; Methylene dichloride;
(d) NH
2oH, methyl alcohol;
Universal method V shown in above-mentioned reaction formula is synthesizing for embodiment 24 and 25.The total Test details that is applicable to each step in the universal method of final compound in synthetic these embodiment has description in embodiment 24 and 25.
By following embodiment, the present invention is illustrated.
Embodiment 1
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN
(a) 4-methoxyphenyl boric acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(b) salt of wormwood, methyl alcohol;
(c) NBS, methylene dichloride;
(d) 3,5-dimethyl isoxazole-4-boric acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(e) 2,2-pair-(4-cyanato-phenyl) propane, Et
3n, methyl-sulphoxide;
(f) BBr
3, methylene dichloride;
Scheme 1
Step (a): the bromo-1-of 3-(benzene sulfonyl)-1H-indoles (500mg, 1.49mmol) and 5mol% tetrakis triphenylphosphine palladium (tetrakis (triphenylphosphine) palladium) are mixed in the degassed DME of 9ml.Gained mixture is stirred and within 5 minutes, is then heated to 85 ℃ under condition of nitrogen gas.At 85 ℃, in 5 minutes, drip and be dissolved in 4-anisole ylboronic acid (1.2eq) and the 5.95ml sodium bicarbonate (1M) in 3ml DME simultaneously.85 ℃ of reaction stirred 10 minutes, be then cooled to room temperature.After DME is concentrated, add water, remaining mixed aqueous solution extracts with DCM.The organic layer merging is concentrated and take EtOAc/ normal heptane (1:9 to 2:8) and with silicon-dioxide, crude product is purified as elutriant.Obtain 3-(4-p-methoxy-phenyl)-1-(the benzenesulfonyl)-1H-indoles of 363 milligrams of white crystals shapes.
Step (b): 3-(4-p-methoxy-phenyl)-1-(benzenesulfonyl)-1H-indoles (200mg, 0.55mmol) and 15eq salt of wormwood are dissolved in 40ml methyl alcohol under condition of nitrogen gas.By gained mixture reflux 16 hours, be then cooled to room temperature, and concentrate drying.Add DCM and salt solution, and with 2M HCl by described mixture acidifying (pH 2-4).Water layer is extracted with DCM, the organic layer merging is concentrated.The EtOAc/n-heptane (1:1) of take is purified crude product with silicon-dioxide as elutriant.Obtain 3-(4-the p-methoxy-phenyl)-1H-indoles of 121.1 milligrams of white solid.
Step (c): 3-(4-p-methoxy-phenyl)-1H-indoles is dissolved in 4ml DCM.In 2 minutes, add on a small quantity several times NBS (0.9eq).Described solvent is concentrated, (the MeCN/H of HPLC for crude product
2o gradient) method is carried out purifying.Obtain the bromo-3-of 2-(4-the p-methoxy-phenyl)-1H-indoles of 103.3 milligrams of white solid.
Step (d): by the bromo-3-of 2-(4-p-methoxy-phenyl)-1H-indoles (93mg, 0.31mmol), 3mol% tetrakis triphenylphosphine palladium and 3,5-dimethyl isoxazole-4-ylboronic acid (3eq) are mixed in the degassed DME of 1.5ml under condition of nitrogen gas.In 5 minutes, drip 1.24ml sodium bicarbonate (1M).Gained mixture stirs after 45 minutes and is cooled to room temperature at 90 ℃.Under nitrogen gas stream environment, evaporate described solvent, and resistates is dissolved in DCM.Through a short silicon-dioxide plug, filter and obtain crude product, this for crude product silicon-dioxide (EtOAc/n-heptane 1:9-3:7) carry out purifying again.Obtain 40.5mg yellow solid shape 4-(3-(4-p-methoxy-phenyl)-1H-indoles-2-yl)-3,5-dimethyl isoxazole.
Step (e): by 4-(3-(4-p-methoxy-phenyl)-1H-indoles-2-yl)-3,5-dimethyl isoxazole (37mg, 0.12mmol) He 2,2-pair-(4-cyanato-phenyl) propane (2,2-bis-(4-cyanatophenyl) propane) (0.6eq) mixes in vial.Add 1.8ml DMSO and Et
3n (3eq), the microwave heating at 120 ℃ of gained mixture.Add 2,2-couple-(4-cyanato-phenyl) propane (5.7eq) and Et
3n (40eq), the microwave heating 25 minutes at 150 ℃ of gained mixture.Add salt solution, and by EtOAc extraction 6 times for water layer.The organic layer merging is with concentrated after dried over sodium sulfate.Gained crude product is dissolved in DCM, and filters with absorbent cotton, then uses silicon-dioxide (EtOAc/n-heptane 1:9-2:8) purifying.Obtain 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN of 25.7mg light yellow solid shape.
Step (f): 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN is dissolved in 3ml DCM, and gained mixture is cooled to-50 ℃.Add BBr
3(5eq), at-50 ℃, stirring reaction is 4.5 hours, then at-20 ℃, stirs 16 hours.Gained mixture is cooled to-78 ℃, successively adds methyl alcohol (90 μ l) and water.DCM extraction 3 times for water layer, the concentrated organic layer merging.Silicon-dioxide for crude product (EtOAc/n-heptane 2:8-3:7) carries out purifying.Obtain 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN of 4.9 milligrams of white solid.ES/MS m/z:330.2 (M+H), 328.3 (M-H);
1h NMR (CDCl
3, 500MHz): 7.75 (m, 1H), 7.67 (m, 1H), 7.51 (m, 1H), 7.41 (m, 1H), 7.20 (m, 2H), 6.88 (m, 2H), 2.28 (s, 3H) and 2.05 (s, 3H).
Embodiment 2 and 3
2-(3,5-dimethyl isoxazole-4-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (E2)
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide (E3)
Scheme 2
Under condition of nitrogen gas, 1 milliliter of anhydrous methanol is joined in 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN (embodiment Isosorbide-5-Nitrae .5mg, 0.01mmol), then add 10eq oxammonium hydrochloride.Add 10eq NaOMe, gained mixture is stirred 4 hours.Solvent is concentrated, and crude product is with CH
2cl
2/ MeOH (97:3 to 96:4) carries out purifying for elutriant with silicon-dioxide.Obtain 2-(3,5-dimethyl isoxazole-4-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (E2) ES/MS m/z:363.5 (M+H) of 2.10 milligrams of white solid, 361.6 (M-H);
1h NMR (MeOD, 500MHz): 7.65 (m 1H), 7.60 (m; 1H), 7.29 (m, 1H); 7.18 (m, 1H), 7.12 (m; 2H), 6.79 (m, 2H); 2.12 (s, 3H), 1.99 (s; 3H) and 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide (E3) ES/MS m/z:348.2 (M+H) of 1.90mg white solid, 346.3 (M-H);
1h NMR (MeOD, 500MHz): 7.93 (m 1H), 7.61 (m, 1H), 7.35 (m, 1H), 7.23 (m, 1H), 7.08 (m, 2H), 6.81 (m, 2H), 2.07 (s, 3H), 2.03 (s, 3H).With regard to embodiment 2, titled reference compound is used
1h-NMR identifies, it shows that this oxime (oxime) product is individual isomer, but and uncertain what obtain is (E) type or (Z) type oxime isomers.
Embodiment 4
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N, N-dimethyl-1H-indoles-1-sulphonamide (E4)
(a)(CH
3)
2NSO
2Cl,NaH,DMF;(b)BF
3.SMe
2,DCM
Scheme 3
Step (a): 0 ℃ under condition of nitrogen gas by 4-(3-(4-p-methoxy-phenyl)-1H-indoles-2-yl)-3,5-dimethyl isoxazole (the intermediate product of step in embodiment 1 (d), 35mg, 0.11mmol) join NaH (25mg, DMF 60% n-heptane solution) (anhydrous, 0.7ml) in suspension.Gained mixture at room temperature stirs 30 minutes, and then is cooled to 0 ℃.Drip dimethylamino SULPHURYL CHLORIDE (2eq).Gained mixture at room temperature stirs 2 hours, is cooled to 0 ℃, adds water termination reaction.Use Isolute phase separator to extract with DCM, by concentrated 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-the p-methoxy-phenyl)-N that obtains quantitative output of the organic layer of merging, N-dimethyl-1H-indoles-1-sulphonamide.
Step (b): by 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-p-methoxy-phenyl)-N, N-dimethyl-1H-indoles-1-sulphonamide (23mg, 0.05mmol) is dissolved in DCM, and gained mixture is cooled to 0 ℃.Drip BF
3sMe
2(0.7ml), reaction mixture is stirred in refrigerator 16 hours.In cold mixture, add several methyl alcohol.Then use Isolute phase separator with H
2o/DCM extracts described mixture.After concentrated, obtain crude product, it uses HPLC (40-70%AcN, 25min gradient) purifying.Obtain 5.6 milligrams of 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N, N-dimethyl-1H-indoles-1-sulphonamide.ES/MS m/z:412.06 (M+H), 410.16 (M-H);
1h NMR (acetone-d6,500MHz): 8.18 (m, 1H), 7.60 (m, 1H), 7.43 (m, 1H), 7.34 (m, 1H), 7.12 (m, 2H), 6.88 (m, 2H), 2.70 (s, 6H), 2.10 (s, 3H) and 2.09 (s, 3H).
Embodiment 5
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formoxime (E5)
(a)DIBAH,DCM;
(b) oxammonium hydrochloride, pyridine, methyl alcohol;
Scheme 4
Step (a): 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN (24mg, 0.07mmol) is dissolved in 5ml DCM under condition of nitrogen gas, and gained mixture is cooled to-60 ℃.Under-60 ℃ of conditions, drip 5eq DIBAH (1M is dissolved in hexane).After removing cryostat, under room temperature, stir described reactant 16 hours.First add 2ml HCl termination reaction (1M), then add 50ml EtOAc.Resulting mixture is filtered and use salt water washing 3 times.Organic layer dried over sodium sulfate, and concentrated solvent.Obtain 18 milligrams of 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formaldehyde.
Step (b): 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formaldehyde (18mg, 0.05mmol) is dissolved in 5ml methyl alcohol.Add 5eq oxammonium hydrochloride and 6eq pyridine.By gained mixture reflux 1.5 hours, then make it be cooled to room temperature.Add 50mlEtOAc, the mixture obtaining is used dried over sodium sulfate with after salt water washing 3 times.Concentrated solvent, crude product carries out purifying with preparation HPLC.Obtain 3.5 milligrams of 2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formoxime.With
1h-NMR identifies titled reference compound, and it shows that this oxime product is individual isomer, but can not determine that what obtain is (E) type or (Z) type oxime isomers.ES/MS m/z:348.01 (M+H), 346.18 (M-H);
1h NMR (MeOD, 500MHz): 8.38 (s, 1H), 8.26 (m, 1H), 7.66 (m, 1H), 7.35 (m, 1H), 7.25 (m, 1H), 7.11 (m, 2H), 6.80 (m, 2H), 2.13 (s, 3H) and 1.99 (s, 3H).
Embodiment 6 and 7
Use is similar to method therefor Preparation Example 6 in above-mentioned synthetic example 4, according to above-mentioned universal method I Preparation Example 7.In described universal method, all experimental details of each step have description in the above-described embodiments.For embodiment 6, titled reference compound
1h-NMR qualification result shows, this oxime product is individual isomer, but uncertain gained is (E) type or (Z) type oxime isomers.
Embodiment 8
2-(3,5-dimethyl isoxazole-4-yl)-N-ethyl-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide (E8)
(a)EtNCO,DMF;(b)BF
3·SMe
2,CH
2Cl
2
Scheme 5
Step (a): by 4-(3-(4-p-methoxy-phenyl)-1H-indoles-2-yl)-3,5-dimethyl isoxazole (15mg, 0.06mmol) and isocyanide acyl ethane (40 μ l) are mixed in 1ml dry DMF under condition of nitrogen gas.Gained mixture is heated 3 hours at 70 ℃.Add 100 μ l isocyanide acyl ethane, continue heated overnight at 70 ℃.Crude product mixture is purified with preparation HPLC.Obtain 8.0mg 2-(3,5-dimethyl isoxazole-4-yl)-N-ethyl-3-(4-p-methoxy-phenyl)-1H-indoles-1-methane amide.
Step (b): 2-(3,5-dimethyl isoxazole-4-yl)-N-ethyl-3-(4-p-methoxy-phenyl)-1H-indoles-1-methane amide (8mg, 0.02mmol) is dissolved in to 8ml DCM, makes gained mixture cooling through ice bath.Drip BF
3sMe
2(0.40ml), gained mixture is stirred 16 hours at 0-2 ℃.Add several methyl alcohol, then add water.Separated each layer, concentrated organic layer.Crude product carries out purifying with preparation HPLC.Obtain 3.4 milligrams of 2-(3,5-dimethyl isoxazole-4-yl)-N-ethyl-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide.ES/MS m/z:376.1 (pos.M+H), 374.2 (neg.M-H);
1h NMR (acetone-d6,500MHz): 7.90 (m, 1H), 7.63 (m, 1H), 7.33 (m, 1H), 7.23 (m, 1H), 7.14 (m, 2H), 6.88 (m, 2H), 3.38 (m, 2H), 2.04 (s, 3H), 2.03 (s, 3H) He 1.16 (t, 3H, J=7.3Hz).
Embodiment 9-15
According to above-mentioned universal method IV Preparation Example 9,13,14 and 15, according to above-mentioned universal method I Preparation Example 10-12.In universal method, all experimental details of each step are described in above-described embodiment.For embodiment 10 and 12, titled reference compound
1h-NMR qualification result shows, this oxime product is individual isomer, but uncertain gained is (E) type or (Z) type oxime isomers.
Embodiment 16-20
According to above-mentioned universal method I Preparation Example 16-20.In described universal method, all experimental details of each step are as described in above-described embodiment.For each embodiment in embodiment 16-20, titled reference compound
1h-NMR qualification result shows, this oxime product is individual isomer, but uncertain gained is (E) type or (Z) type oxime isomers.
Embodiment 21
The chloro-2-of 5-(2,4-thioxene-3-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1 hydrogen-indoles-1-azomethine acid amides (E21)
According to scheme 1, obtain
(a) NaH, 2,2-pair-(4-cyanato-phenyl) propane, THF;
(b)BF
3.SMe
2;DCM;
(c)NH
2OH,DCM
Scheme 6
Step (a): at 0 ℃ by NaH (6.11mg, 0.25mmol) join in anhydrous THF (1ml) and stir, dropping is dissolved in the chloro-2-(2 of 5-in anhydrous THF (2ml), 4-thioxene-3-yl)-3-(4-p-methoxy-phenyl)-1H-indoles (72mg, 0.20mmol), gained mixture stirs 5 minutes at 0 ℃.Dropping is dissolved in 2 in anhydrous THF (2ml), and 2-pair-(4-cyanato-phenyl) propane (70.8mg, 0.25mmol), gained mixture at room temperature stirs 9 hours.Successively add NH
4cl (aq, sat) and salt solution, gained aqueous mixture extracts with DCM.Concentrated solvent, silicon-dioxide for crude product (EtOAc/ normal heptane 1:9) carries out purifying.Obtain 72 milligrams of chloro-2-of 5-(2,4-thioxene-3-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN.
Step (b): the chloro-2-of 5-(2,4-thioxene-3-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN (75mg, 0.19mmol) is dissolved in 4ml DCM, and gained mixture is cooling through ice bath.Drip BF
3.SMe
2(0.20ml, 1.91mmol), gained mixture at room temperature stirs 24 hours.At 0 ℃, first add several methyl alcohol, add NaHCO again
3(aq, sat) and salt solution.Separated each layer, and organic layer is concentrated.Silicon-dioxide for crude product (MeOH/DCM 1:99) purifying.Obtain 42.0 milligrams of chloro-2-of 5-(2,4-thioxene-3-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN.
Step (c): at 0 ℃ by azanol (the 16.3M aqueous solution, 0.69ml, 11.0mmol) join the chloro-2-(2 of 5-that is dissolved in DCM (5ml), 4-thioxene-3-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN (42mg, 0.11mmol) in solution, and at 0 ℃ reaction stirred 65 hours.Add salt solution, and gained aqueous mixture is extracted with DCM.Concentrated solvent, crude product is purified and is obtained the chloro-2-of 5-(2,4-thioxene-3-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (7.0mg, 35%) with preparation HPLC.Titled reference compound
1h-NMR qualification result shows, this oxime product is individual isomer, but uncertain gained is (E) type or (Z) type oxime isomers.ES/MS m/z:414.5; 412.4 (M+H), 412.3; 409.9 (M-H);
1h NMR (acetone-d6,500MHz): 7.65 (d, 1H, J=2.1Hz), 7.58 (d, 1H, J=8.8Hz), 7.25 (dd, 1H, J=8.8,2.1Hz), 7.10 (m, 2H), 6.83-6.80 (m, 3H), 2.18 (s, 3H) He 1.95 (d, 3H, J=1.1Hz).
Embodiment 22 and 23
According to above-mentioned universal method I Preparation Example 22 and 23.In described universal method, all experimental details of each step are described to some extent in above-described embodiment 1 and 21.For each embodiment in embodiment 22 and 23, titled reference compound
1h-NMR identifies that structure shows, this oxime product is individual isomer, but uncertain gained is (E) type or (Z) type oxime isomers.
Embodiment 24 and 25
2-(3,5-dimethyl isothiazole-4-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (E24)
2-(3,5-dimethyl isothiazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide (E25)
According to scheme 1, obtain
(a) NaH, 2,2-pair-(4-cyanato-phenyl) propane, THF;
(b) 3,5-dimethyl isothiazole-4-ylboronic acid, Pd (PPh
3)
4, sodium bicarbonate, DME/H
2o;
(c) BF
3.SMe
2; Methylene dichloride;
(d) NH
2oH, methyl alcohol;
Scheme 7
Step (a): at 0 ℃ by NaH (18.35mg, 0.76mmol) be dissolved in anhydrous THF (1ml) and stir, dropping is dissolved in the bromo-3-of 2-(4-the p-methoxy-phenyl)-1H-indoles (210mg, 0.69mmol) in anhydrous THF (4.5ml).Gained mixture stirs 5 minutes at 0 ℃, then drips and is dissolved in 2 in anhydrous THF (4.5ml), 2-pair-(4-cyanato-phenyl) propane (251mg, 0.90mmol).After adding water, gained mixture is stirred 30 minutes.Add salt solution and extract gained aqueous mixture with DCM.Concentrated solvent, silicon-dioxide for crude product (EtOAc/ normal heptane 1:4) purifying.Obtain 198 milligrams of bromo-3-of 2-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN.
Step (b): under condition of nitrogen gas, by the bromo-3-of 2-(4-p-methoxy-phenyl)-1H-indoles-1-nitrile (70.0mg, 0.21mmol), tetrakis triphenylphosphine palladium (24.7mg, 0.21mmol) He 3,5-dimethyl isothiazole-4-ylboronic acid (102.3mg, 0.43mmol) is mixed in 3.5ml DME and 0.86ml sodium bicarbonate (1M).By the microwave heating 20 minutes at 120 ℃ of the mixture of gained.Evaporating solvent, is dissolved in resistates in DCM.With short silicon-dioxide plug, filter and obtain crude extract, this for crude product silicon-dioxide (EtOAc/ normal heptane 1:4) carry out purifying.Obtain 38.0mg2-(3,5-dimethyl isothiazole-4-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN.
Step (c): 2-(3,5-dimethyl isothiazole-4-yl)-3-(4-p-methoxy-phenyl)-1H-indoles-1-formonitrile HCN (38mg, 0.11mmol) is dissolved in 10ml DCM, and gained mixture ice bath is cooling.Drip BF
3sMe
2(0.56ml, 5.29mmol), gained mixture stirs 16 hours at 0-2 ℃.Splash into several methyl alcohol, then add saturated aqueous solution of sodium bicarbonate.Separated each layer, organic layer is concentrated.Crude product carries out purifying with preparation HPLC.Obtain 18.0 milligrams of 2-(3,5-dimethyl isothiazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN.
Step (d): by azanol (the 16.3M aqueous solution, 0.33ml, 5.21mmol) join the 2-(3 that is dissolved in methyl alcohol (2mL), 5-dimethyl isothiazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN (18mg, 0.05mmol), at 130 ℃, microwave reaction stirred is 20 minutes.Gained mixture is purified and is obtained E24:2-(3 with preparation HPLC; 5-dimethyl isothiazole-4-yl)-N '-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides (7.0mg; 35%): ES/MS m/z 379.11 (M+H), 377.14 (M-H);
1h NMR (acetone-d6,500MHz): 7.70 (dd, 1H; J=7.9,1.0Hz), 7.59 (dd; 1H, J=9.0,0.9Hz); 7.29 (m, 1H), 7.20 (m; 1H); 7.09 (m, 2H), 6.81 (m; 2H); 2.30 (s, 3H) and 2.16 (s, 3H); with E25 2-(3; 5-dimethyl isothiazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide (5mg, 26%): ES/MS m/z 364.11 (M+H), 362.14 (M-H);
1h NMR (acetone-d6,500MHz): 8.12 (d, 1H, J=8.4Hz), 7.67 (d, 1H, J=7.9Hz), 7.36 (m, 1H), 7.26 (m, 1H), 7.05 (m, 2H), 6.83 (m, 2H) and 2.21 (s, 6H).For each titled reference compound,
1h-NMR qualification result shows, this amidoxime product is individual isomer, but uncertain resulting be (E) type or (Z) type oxime isomers.
In conjunction with activation analysis 1: estrogen receptor binding affinity is measured
Estrogen receptor ligands is in conjunction with mensuration be designed to the to glimmer form of approaching assay method (scintillation proximity assay, SPA), its used tritium-labeled estradiol (
3h-E2) and recombinant expressed biotinylated estrogen receptor binding domains.People ER α (ER α-LBD, pET-N-AT #1, aa 301-595) and ER β (ER β-LBD, pET-N-AT #1, aa 255-530) binding domains of albumen is by the intestinal bacteria (BL21 in the 2xLB substratum that is added with 50 μ M vitamin Hs at 22 ℃, DE3, pBirA) produce.IPTG (0.55mM) induction is after 3 hours, with centrifugal 15 minutes collecting cells cell precipitation is frozen at-20 ℃ of 7300g.After being suspended with 50ml Extraction buffer (50mM Tris, pH 8.0,100mM KCl, 4mM EDTA, 4mM DDT and 0.1mM PMSF), 5g cell extracts ER α and ER β.Described cell suspension through twice miniflow homogeneous instrument (Microfluidizer M-110L, Microfluidics) after with 15,000g centrifugal 60 minutes.Supernatant liquor packing is kept to-70 ℃.
With measuring damping fluid (18mM K
2hPO
4, 2mM KH
2pO
4, 20mM Na
smoO
4, 1mM EDTA, 1mM TCEP) respectively according to dilution proportion ER α-LBD of 1:676 and 1:517 and ER β-LBD extract.The acceptor density of dilution should be 900fmol/l.By described extract and coated polyvinyl toluene (polyvinyltoluene) the SPA pearl (RPNQ0007, GE Healthcare) of streptavidin with the concentration of 0.43mg/ml preincubate 1 hour at room temperature.
The concentration range of test compounds is 37.5pM to 157 μ M.Test compounds liquid storage is to make with 100%DMSO, and concentration is 5 times of the required final concentration of test analysis.In the test hole of 384 orifice plates, the amount of DMSO accounts for 20%.Toward successively adding the aliquots containig of 18 μ l test compounds and acceptor/SPA pearl mixture of 35 μ l preincubates in assay plate, finally adding 35 μ l concentration, be 3nM
3h-E2.With plastics sealer residence, state plate, under 1000rpm centrifugal 1 minute, then under room temperature on vibrator equilibrate overnight.The next morning, by described plate with 2000rpm centrifugal 5 minutes, then tests with the flat board flicker numeration instrument of for example PerkinElmer Microbeta 1450Trilux.
For replacing 3[H from acceptor] compound of-E2, apply non-linear four parameter logical models (non-linear four parameter logistic model) and calculate IC
50-value (suppress 50% 3[H]-E2 in conjunction with required concentration); B=((bmax-bmin)/(1+ (I/IC
50) S))+bmin, I is concentration, the IC of the binding inhibitors that adds
50inhibitor concentration, the S that is maximum combined one half is slope factor (slope factor).Described Microbeta-equipment generates average cpm(count per minute) value/minute, and proofread and correct for the individual difference between detector, thereby generate calibrated cpm value
Turn live (tansactivation) and measure 1: turning to live and measure with mankind's embryo kidney 293 cell of pERE-ALP and mankind's estrogen receptor alpha stable transfection
The insertion sequence that expression vector pMThER α contains the wild-type mankind's estrogen receptor alpha that has lacked leader.The P-ALP (placental alkaline phosphatase, ALP) that pERE-ALP report construct contains secreted form and the gene of vitellin(Vt) estrogen response element (ERE).The transfection of mankind's embryo kidney 293 cell is divided into two steps.First, obtain with pERE-ALP report construct and for the stable clone mixture of the pSV2-Neo transfection of screening for screening.Second step, with pMThER α and for this stable clone's mixture of pKSV-Hyg resistance carrier transfection of screening for screening.All transfections are all applied Lipofectamine (Invitrogen) and are operated according to the specification sheets of manufacturers.Choosing the clone who simultaneously contains pERE-ALP and pMThER α measures for turning to live.
Concentration by described cell with 12500 cells in every hole is seeded in Ham ' s F12 Coon ' the s improved culture medium that contains 10% foetal calf serum (FBS), 2mM L-glutaminate and the 50 μ g/ml gentamicins of processing with the coated charcoal end (DCC) of dextran (not containing phenol red) of 384 orifice plates.Hatch after 24 hours (37 ℃, 5% CO
2) discard inoculation medium, replace with and contain 1.5% DCC-FCS, 2mM L-glutaminate and be added with 100U/ml penicillin and 20 μ l Ham ' s F12Coon ' s improved culture medium of 100 μ g/ml Streptomycin sulphates (not containing phenol red).By the compound of selecting, with scope, 12 concentration in 3.3pM to 33 μ M join in hole.By described compound dissolution, in 100% dimethyl sulfoxide (DMSO) (DMSO), the final concentration of DMSO in measuring liquid is 0.1%.Hatch 72 hours (37 ℃, 5%CO
2) after, described chemoluminescence for substratum (chemiluminescence) assay ALP is active; The aliquots containig of cell culture medium described in 10 μ l and 100 μ l are measured to damping fluid (0.1M diethanolamine, 1mM magnesium chloride) and 0.5mM 3-(4-methoxy spiral shell 1,2-dioxetane-3,2 '-(5 '-chlorine)-tri-ring [3.3.1.13,7] last of the ten Heavenly stems-4-yl) disodium phenylphosphate (CSPD) (Tropix, Applied Biosystems) mix, at 37 ℃, hatch 20 minutes, under room temperature, hatch 15 minutes again, then use Wallac Microbeta Trilux 1450-028 (PerkinElmer) to carry out chemiluminescence signal measurement (every Kong Yimiao).According to XLfit software 2.0 editions (IDBS) or more highest version with four parameter logical models to the maximum half (EC of effective concentration of the curve calculation of concentration-response data matching
50) numerical value.
Turning and live measuring 2: turning to live and measure with mankind's embryo kidney 293 cell of pERE2-ALP and mankind's erss stable transfection
Express the HEK293 stable cell lines (CRL-1573 of report carrier pERE2-ALP and mankind's erss (hER β 530); American Type Culture Collection) preparation method (Mol Pharmacol 1998,54,105-112 on the books; Endocrinology 2002,143,1558-1561).
Concentration by described cell with 12500 cells in every hole is seeded in Ham ' s F12 Coon ' the s improved culture medium that contains 10% foetal calf serum (FBS), 2mM L-glutaminate and the 50 μ g/ml gentamicins of processing with the coated charcoal end (DCC) of dextran (not containing phenol red) of 384 orifice plates.Hatch after 24 hours (37 ℃, 5% carbonic acid gas) discard inoculation medium, replace with and contain 1.5%DCC-FCS, 2mM L-glutaminate and be added with 100U/ml penicillin and 20 μ l Ham ' s F12 Coon ' s improved culture medium of 100 μ g/ml Streptomycin sulphates (not containing phenol red).By the compound of selecting, with scope, 12 concentration in 3.3pM to 33 μ M join in hole.By described compound dissolution, in 100% dimethyl sulfoxide (DMSO) (DMSO), the final concentration of DMSO in measuring liquid is 0.1%.Hatch 72 hours (37 ℃, 5%CO
2) after, described substratum is active with determination by way of chemiluminescence analysis ALP.The aliquots containig of conditioned medium described in 10 μ l and 100 μ l are measured to damping fluid (0.1M diethanolamine, 1mM magnesium chloride) and 0.5mM 3-(4-methoxy spiral shell 1,2-dioxetane-3,2 '-(5 '-chlorine)-tri-ring [3.3.1.13,7] last of the ten Heavenly stems-4-yl) disodium phenylphosphate (CSPD) (Tropix, Applied Biosystems) mix, then at 37 ℃, hatch 20 minutes, under room temperature, hatch 15 minutes again, then use Wallac Microbeta Trilux 1450-028 (PerkinElmer) to carry out chemiluminescence signal measurement (every Kong Yimiao).The ALP activity of expressing in LCPS is directly proportional to the ALP expression level of cell.According to XLfit software 2.0 editions (IDBS) or more highest version with four parameter logical models to the maximum half (EC of effective concentration of the curve calculation of concentration-response data matching
50) numerical value.
The compound of embodiment 1-24 is being tested in conjunction with mensuration 1 and in turning the mensuration 1 and 2 of living.
The compound of embodiment 1-24 demonstrates following one or more activity:
(i) in conjunction with mensuration 1, with the binding affinity IC of alpha hypotype estrogen receptor
50scope is: 1 to 10,000nM;
(ii) in conjunction with mensuration 1, with the binding affinity IC of β hypotype estrogen receptor
50scope is: 1 to 10,000nM;
(iii) in turning mensuration 1 alive, the effect EC to alpha hypotype estrogen receptor
50scope is: 1 to 10,000nM;
(iv) in turning mensuration 2 alive, the effect EC to β hypotype estrogen receptor
50scope is: 1 to 10,000nM;
Preferred embodiment of the invention compound is at above-mentioned IC
50in scope, under low concentration, demonstrate those compounds to the binding affinity of β hypotype estrogen receptor.For example, in conjunction with the compound of measuring embodiment 1-3,5-8,10-12,15-18 and 20-24 in 1 at IC
50be to demonstrate the binding affinity to β hypotype estrogen receptor in 1 to 200nM scope.
Preferred embodiment of the invention compound be those in conjunction with in measuring 1 for the selectivity of β hypotype estrogen receptor the compound higher than alpha hypotype estrogen receptor.For example, embodiment 1-3,6-8,10-12, the compound of 15-18 and 20-24 is being 50 or higher in conjunction with demonstrating the selectivity of β hypotype estrogen receptor in measuring.
Preferred embodiment of the invention compound is that those are at above-mentioned EC
50in scope, under low concentration, demonstrate the compound to the effect of β hypotype estrogen receptor.For example, turn and live to measure in 2 embodiment 1-13 and 15-24 at EC
50be to demonstrate the effect to β hypotype estrogen receptor in 0.1 to 200nM scope; Embodiment 2-3,5-8, the compound of 10-12 and 16-24 is at EC
50be to demonstrate effect in 0.1 to 10nM scope.
Preferred embodiment of the invention compound for those turn live to measure 1 and 2 in to the selectivity of β hypotype estrogen receptor the compound higher than alpha hypotype estrogen receptor.For example, turn live to measure in the compound of embodiment 1-3 and 6,8,10-13,15-20 and 22-24 to demonstrate the selectivity of β hypotype estrogen receptor be 50 or higher.
Claims (21)
1. the compound in formula (I) or its pharmaceutically useful salt,
Wherein, R
1be selected from C
1-6alkyl, C
2-6thiazolinyl, C
2-6alkynyl, halo C
1-6alkyl, halo C
2-6thiazolinyl, phenyl and 5-10 unit heterocyclic radical, wherein said phenyl or heterocyclic radical group can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from halogen, cyano group, nitro and C
1-6alkyl;
R
2be selected from cyano group ,-CHO ,-CH=N-OH ,-SO
2c
1-4alkyl ,-C (NH
2)=N-OH ,-C (O) N (R
c)
2and SO
2n(R
c)
2;
R
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10in each independently selected from hydrogen or halogen;
Each R
cindependently selected from hydrogen and C
1-6alkyl.
2. claimed compound in claim 1, wherein said halo C
1-6alkyl is dihalo C
1-6alkyl or three halo C
1-6alkyl.
3. claimed compound in claim 1, wherein said halo C
2-6thiazolinyl is dihalo C
2-6thiazolinyl or three halo C
2-6thiazolinyl.
4. claimed compound in claim 1, wherein R
1be selected from C
2-6thiazolinyl, phenyl and 5-6 unit heterocyclic radical,
Wherein said phenyl or heterocyclic radical can be unsubstituted or by 1-3 substituting group replacement, each substituting group is independently selected from cyano group and C
1-6alkyl; With
R
2be selected from cyano group ,-CH=N-OH ,-SO
2c
1-4alkyl ,-C (NH
2)=N-OH ,-C (O) N (R
c)
2and SO
2n(R
c)
2.
5. the claimed compound of any one, wherein R in claim 1-4
2represent cyano group ,-CH=N-OH ,-C (O) N (R
c)
2or-C (NH
2)=N-OH.
6. claimed compound in claim 5, wherein R
2representative-CH=N-OH or-CONH
2.
7. the claimed compound of any one, wherein R in claim 1-4
1represent C
2-6thiazolinyl, phenyl or 5 yuan of heterocyclic radicals, wherein said phenyl or heterocyclic radical group can be unsubstituted or by 1-2 substituting group replacement, each substituting group is independently selected from C
1-6alkyl.
8. claimed compound in claim 7, wherein R
1represent phenyl or 5 yuan of heterocyclic radicals, wherein said phenyl or heterocyclic radical group are replaced by 1-2 substituting group, and described substituting group is C
1-6alkyl.
9. claimed compound in claim 8, wherein R
1represent phenyl or 5 yuan of heterocycles, wherein said phenyl or heterocyclic radical group are replaced by 2 substituting groups, and described substituting group is methyl.
10. claimed compound in claim 9, wherein R
1represent 2,6-3,5-dimethylphenyl, 3,5-dimethyl isoxazole-4-base, 2,4-dimethyl-thiene-3-yl-or 3,5-dimethyl isothiazole-4-base.
Claimed compound, wherein R in any one in 11. claim 1-4
3, R
4, R
5, R
6, R
7, R
8, R
9and R
10in each independently selected from hydrogen, Cl and F.
Claimed compound in 12. claims 11, wherein R
3, R
4, R
5and R
6in each represent hydrogen; R
7, R
8, R
9and R
10in one or two represent fluorine, remaining represents hydrogen.
Claimed compound in 13. claims 1, it is any one or its pharmaceutically useful salt in following compound:
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formonitrile HCN;
2-(3,5-dimethyl isoxazole-4-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N, N-dimethyl-1H-indoles-sulphonamide;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-formoxime;
4-(2-(3,5-dimethyl isoxazole-4-yl)-1-(methyl sulphonyl)-1H-indol-3-yl) phenol;
2-((Z)-but-2-ene-2-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isoxazole-4-yl)-N-ethyl-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N-Methyl-1H-indole-1-methane amide;
2-(2,4-thioxene-3-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(2,4-thioxene-3-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide;
2-(2,6-3,5-dimethylphenyl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N-sec.-propyl-1H-indoles-1-methane amide;
2-(3,5-dimethyl isoxazole-4-yl)-3-(4-hydroxyphenyl)-N-amyl group-1H-indoles-1-methane amide;
2-(2,4-thioxene-3-yl)-N-ethyl-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide;
3-(the fluoro-4-hydroxyphenyl of 3,5-bis-)-2-(3,5-dimethyl isoxazole-4-yl)-N'-hydroxyl-1H-indoles-1-azomethine acid amides;
3-(the fluoro-4-hydroxyphenyl of 2,3-bis-)-2-(3,5-dimethyl isoxazole-4-yl)-N'-hydroxyl-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isoxazole-4-yl)-3-(the fluoro-4-hydroxyphenyl of 2-)-N'-hydroxyl-1H-indoles-1-azomethine acid amides;
3-(the fluoro-4-hydroxyphenyl of 2,5-bis-)-2-(3,5-dimethyl isoxazole-4-yl)-N'-hydroxyl-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isoxazole-4-yl)-3-(the fluoro-4-hydroxyphenyl of 3-)-N'-hydroxyl-1H-indoles-1-azomethine acid amides;
The chloro-2-of 5-(3,5-dimethyl isoxazole-4-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(2,4-dimethyl furan-3-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isothiazole-4-yl)-N'-hydroxyl-3-(4-hydroxyphenyl)-1H-indoles-1-azomethine acid amides;
2-(3,5-dimethyl isothiazole-4-yl)-3-(4-hydroxyphenyl)-1H-indoles-1-methane amide.
14. 1 kinds of pharmaceutical compositions, it contains claimed compound and a kind of pharmaceutically acceptable carrier of any one in aforementioned claim.
In 15. claims 1 to 13, the claimed compound of any one is for the preparation of the purposes of the medicament for the treatment of or the prevention illness relevant with estrogen receptor activity relative disease or obstacle.
The claimed composition of 16. claims 14 is for the preparation of the purposes of the medicament for the treatment of or the prevention disease relevant to estrogen receptor activity or obstacle.
In 17. claims 1 to 13 the claimed compound of any one with the form through mark the purposes for the preparation of the diagnostic reagent in order to the diagnosis disease relevant with estrogen receptor activity or the relevant illness of obstacle, or in claim 1 to 13 the claimed compound of any one or this compound through mark pattern for the preparation of for differentiating that the method for estrogen receptor ligands is used as the purposes of the reagent of reference compound.
The claimed purposes of any one in 18. claims 15 to 16, the wherein said disease relevant with estrogen receptor activity or the relevant illness of obstacle are selected from bone loss, fracture, cartilage degeneration, hot flush, LDL-C level increases, cardiovascular disorder, Cognitive function damage, brain degenerative disease, vascular smooth muscle cell curing, obesity, incontinence, anxiety disorder, dysthymia disorders, somnopathy, irritability, impulsion, indignation management, dysaudia, Spinal injury, autoimmune disorder, inflammation, sexual dysfunction, hypertension, retinal degeneration, lower urinary tract syndrome, bladder hyperactivity hyperkinesia, bladder pain syndrome, wound healing, chronic pain, inflammatory neurodynia and attention deficit.
The claimed purposes of any one in 19. claims 15 to 16, the wherein said disease relevant with estrogen receptor activity or the relevant illness of obstacle are selected from osteoporosis, endometriosis, leiomyoma of uterus, the age mild cognitive impairment of being correlated with, restenosis, gynaecomastia, study on perimenopausal depressive disorder, post-natal depression, premenstrual syndrome, manic dysthymia disorders, dull-witted, compulsive behavior, the many moving attention deficit disorders of companion, multiple sclerosis, Parkinson's disease, alzheimer's disease (Alzheimer ' s disease), Huntington's disease, amyotrophic lateral sclerosis, apoplexy, IBD, IBS, lung cancer, colorectal carcinoma, mammary cancer, uterus carcinoma, prostate cancer, the bile duct cancer form that is called as cholangiocarcinoma, benign prostatic hyperplasia, interstitial cystitis, vaginal atrophy, Sepsis, ovarian cancer, melanoma and lymphoma.
The purposes that 20. claims 17 are claimed, the wherein said disease relevant with estrogen receptor activity or the relevant illness of obstacle are selected from bone loss, fracture, cartilage degeneration, hot flush, LDL-C level increases, cardiovascular disorder, Cognitive function damage, brain degenerative disease, vascular smooth muscle cell curing, obesity, incontinence, anxiety disorder, dysthymia disorders, somnopathy, irritability, impulsion, indignation management, dysaudia, Spinal injury, autoimmune disorder, inflammation, sexual dysfunction, hypertension, retinal degeneration, lower urinary tract syndrome, bladder hyperactivity hyperkinesia, bladder pain syndrome, wound healing, chronic pain, inflammatory neurodynia and attention deficit.
The purposes that 21. claims 17 are claimed, the wherein said disease relevant with estrogen receptor activity or the relevant illness of obstacle are selected from osteoporosis, endometriosis, leiomyoma of uterus, the age mild cognitive impairment of being correlated with, restenosis, gynaecomastia, study on perimenopausal depressive disorder, post-natal depression, premenstrual syndrome, manic dysthymia disorders, dull-witted, compulsive behavior, the many moving attention deficit disorders of companion, multiple sclerosis, Parkinson's disease, alzheimer's disease (Alzheimer ' s disease), Huntington's disease, amyotrophic lateral sclerosis, apoplexy, IBD, IBS, lung cancer, colorectal carcinoma, mammary cancer, uterus carcinoma, prostate cancer, the bile duct cancer form that is called as cholangiocarcinoma, benign prostatic hyperplasia, interstitial cystitis, vaginal atrophy, Sepsis, ovarian cancer, melanoma and lymphoma.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0917575A GB0917575D0 (en) | 2009-10-07 | 2009-10-07 | Novel estrogen receptor ligands |
GB0917575.3 | 2009-10-07 | ||
GB1004377.6 | 2010-03-16 | ||
GBGB1004377.6A GB201004377D0 (en) | 2010-03-16 | 2010-03-16 | Novel estrogen receptor ligands |
PCT/EP2010/064939 WO2011042473A2 (en) | 2009-10-07 | 2010-10-06 | Novel estrogen receptor ligands |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102791688A CN102791688A (en) | 2012-11-21 |
CN102791688B true CN102791688B (en) | 2014-11-12 |
Family
ID=43857210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080045502.6A Expired - Fee Related CN102791688B (en) | 2009-10-07 | 2010-10-06 | Estrogen receptor ligands |
Country Status (10)
Country | Link |
---|---|
US (1) | US8710243B2 (en) |
EP (1) | EP2486010B1 (en) |
JP (1) | JP5687704B2 (en) |
CN (1) | CN102791688B (en) |
AR (1) | AR078537A1 (en) |
DK (1) | DK2486010T3 (en) |
ES (1) | ES2744219T3 (en) |
IN (1) | IN2012DN02555A (en) |
TW (1) | TW201124404A (en) |
WO (1) | WO2011042473A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
CA2932224A1 (en) | 2013-12-05 | 2015-06-11 | Karo Pharma Ab | Estrogen receptor beta agonists for use in treating mesothelioma |
US10758496B2 (en) | 2014-09-02 | 2020-09-01 | The Regents Of The University Of California | Estrogen receptor ligand treatment for neurodegenerative diseases |
WO2016097036A1 (en) * | 2014-12-17 | 2016-06-23 | Karo Bio Ab | Estrogen receptor ligand for use in treating melanoma |
US11624095B2 (en) | 2017-09-27 | 2023-04-11 | Case Western Reserve University | Method of quantifying HIV reservoirs by induced transcription based sequencing |
CN111704648B (en) * | 2020-06-23 | 2022-02-15 | 武汉大学 | Proteolysis targeting chimera compound with oxido bicycloheptene compound as estrogen receptor ligand, preparation method and application |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001122855A (en) | 1999-10-27 | 2001-05-08 | Japan Tobacco Inc | Indole compound and its pharmaceutical use |
US20030220377A1 (en) * | 2002-05-08 | 2003-11-27 | Richard Chesworth | Indole compounds and their use as estrogen agonists/antagonists |
FR2868779B1 (en) * | 2004-04-09 | 2008-08-22 | Pierre Fabre Medicament Sa | PROCESS FOR SYNTHESIS AND INTERMEDIATES OF BENZOXATHIEPINES |
ITMI20040874A1 (en) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION |
EP1779848A1 (en) * | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
CN101374808B (en) * | 2006-01-24 | 2011-05-25 | 伊莱利利公司 | Indole sulfonamide modulators of progesterone receptors |
JP2010505898A (en) | 2006-10-13 | 2010-02-25 | カロ バイオ アクチェブラーグ | 2-Phenylindene derivatives useful as estrogen receptor ligands |
US20100210524A1 (en) | 2007-07-20 | 2010-08-19 | Theresa Apelqvist | Novel estrogen receptor ligands |
GB0806656D0 (en) | 2008-04-11 | 2008-05-14 | Karobio Ab | Novel estrogen receptor ligands |
BRPI0910656A2 (en) | 2008-04-16 | 2019-09-24 | Karobio Ab | "Estrogen receptor binding compounds, their use and pharmaceutical composition" |
GB0817221D0 (en) | 2008-09-19 | 2008-10-29 | Karobio Ab | Novel estrogen receptor ligands |
-
2010
- 2010-10-06 DK DK10762668.1T patent/DK2486010T3/en active
- 2010-10-06 TW TW099133973A patent/TW201124404A/en unknown
- 2010-10-06 JP JP2012532582A patent/JP5687704B2/en not_active Expired - Fee Related
- 2010-10-06 AR ARP100103630A patent/AR078537A1/en unknown
- 2010-10-06 CN CN201080045502.6A patent/CN102791688B/en not_active Expired - Fee Related
- 2010-10-06 US US13/500,471 patent/US8710243B2/en not_active Expired - Fee Related
- 2010-10-06 IN IN2555DEN2012 patent/IN2012DN02555A/en unknown
- 2010-10-06 ES ES10762668T patent/ES2744219T3/en active Active
- 2010-10-06 EP EP10762668.1A patent/EP2486010B1/en not_active Not-in-force
- 2010-10-06 WO PCT/EP2010/064939 patent/WO2011042473A2/en active Application Filing
Non-Patent Citations (2)
Title |
---|
Hydroxy-3-(hydroxyphenyl)indoles.R elationship between Structure and Estrogen Receptor Affinity;Josef Strohmeier et al.,;《Arch. Pharm.》;19851231;第318卷;421-431 * |
Josef Strohmeier et al.,.Hydroxy-3-(hydroxyphenyl)indoles.R elationship between Structure and Estrogen Receptor Affinity.《Arch. Pharm.》.1985,第318卷 * |
Also Published As
Publication number | Publication date |
---|---|
US20120202861A1 (en) | 2012-08-09 |
CN102791688A (en) | 2012-11-21 |
WO2011042473A3 (en) | 2011-06-03 |
EP2486010B1 (en) | 2019-06-12 |
AR078537A1 (en) | 2011-11-16 |
DK2486010T3 (en) | 2019-09-23 |
TW201124404A (en) | 2011-07-16 |
IN2012DN02555A (en) | 2015-08-28 |
WO2011042473A2 (en) | 2011-04-14 |
JP5687704B2 (en) | 2015-03-18 |
EP2486010A2 (en) | 2012-08-15 |
ES2744219T3 (en) | 2020-02-24 |
US8710243B2 (en) | 2014-04-29 |
JP2013507335A (en) | 2013-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102066323B (en) | Novel estrogen receptor ligands | |
CN102791688B (en) | Estrogen receptor ligands | |
CN102239164B (en) | 2H-chromene compound and derivative thereof | |
CN102648183B (en) | As the substituted pyrazolecarboxylic of estrogen receptor ligands | |
WO2011042474A1 (en) | Novel estrogen receptor ligands | |
CN101631545A (en) | The toluene fulfonate of therapeutic compound and pharmaceutical composition thereof | |
KR102446027B1 (en) | Nitrogen-containing 6-membered ring compound | |
CN101360419A (en) | Chemical compounds | |
CN1989103A (en) | Indole-2 -carboxamidine derivatives as nmda receptor antagonists | |
CN102216268A (en) | Novel estrogen receptor ligands | |
CN103842341B (en) | Estrogen receptor ligands | |
CN101910170A (en) | (1,4-diazabicyclo [3.2.2] ninth of the ten Heavenly Stems-6-alkene-4-yl)-heterocyclic radical-ketone part that is used for the treatment of the nicotinic acetylcholine receptor of disease | |
CN103360342B (en) | 3-cyano-aniline alkylaryl bridged piperazine derivatives and preparing the application in medicine | |
JP4624979B2 (en) | Benzofuranoxyethylamine as an antidepressant and anxiolytic | |
CN102532073A (en) | Ethylene derivative serving as selective estrogen receptor modulators (SERMs) | |
Prudhomme et al. | Design, synthesis and biological evaluation of conformationnally-restricted analogues of E7010 as inhibitors of tubulin assembly (ITA) and vascular disrupting agents (VDA) | |
TW434230B (en) | 5-aminoethoxy-1,4-dihydroquinoxaline-2,3-diones | |
TWI300776B (en) | Novel compounds | |
BR112020012405B1 (en) | Nitrogen-containing 6-membered cyclic compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141112 Termination date: 20201006 |
|
CF01 | Termination of patent right due to non-payment of annual fee |